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PREFACE
Lysophospholipids (LPLs) are lipid messengers that are 
present in the extracellular environment and play impor-
tant roles in cell signaling. By binding to specific recep-
tors, the effects of LPLs are translated into specific cellular 
responses. Lysophosphatidic acid (LPA) and sphingosine-
1-phosphate (S1P) are LPLs that regulate a variety of sig-
naling pathways implicated in both health and disease. 
As a consequence, LPLs, their receptors and the enzymes 
that generate or degrade them, are attractive drug targets 
for various diseases. 
This thesis focuses on autotaxin (ATX), the main en-
zyme responsible for the production of LPA. The studies 
described in this thesis aim at characterizing the bio-
chemical and functional properties of ATX, to advance our 
understanding of the molecular actions of ATX in (patho)
physiology. This chapter introduces LPA production and 
signaling, elaborates on ATX processing, activity and regu-
lation, and highlights the role of ATX-LPA receptor signal-




LPA (monoacyl-sn-glycero-3-phosphate) is a structurally simple phospholipid, composed of 
a phosphate headgroup, a glycerol backbone and a fatty acyl chain (Fig. 1A). Originally, LPA 
was known as an intermediate in intracellular lipid metabolism, and only later recognized 
as an extracellular bioactive lipid mediator and major active component of serum.  LPA has 
growth factor-like activities and stimulates a wide variety of cellular responses; including 
cell proliferation, survival, migration, morphological changes, wound healing, cytokine and 
chemokine secretion, increased endothelial permeability and inhibition of gap-junctional 
communication (1). More than a decade after the initial discovery of LPA as a bioactive lipid 
mediator, ATX was found to be identical to plasma lysophospholipase D (lysoPLD), the main 
enzyme responsible for producing bioactive LPA (2;3). 
LPA Production
LPA is present in serum, plasma, saliva, follicular fluid, seminal plasma, mildly oxidized 
LDL (1) and malignant effusions, such as ascitic fluid from ovarian cancer patients (4;5). 
LPA is primarily produced in plasma, mainly via lysophospholipase D (lysoPLD) activity by 
hydrolyzing lysophosphatidylcholine (LPC) (6). LPC is a lysophospholipid composed of a 
choline head group, a phosphate group, a glycerol backbone and a fatty acyl chain (Fig. 
1B). In the extracellular LPA production pathway, phospholipids are first converted to 
lysophospholipids by phospholipase A1 (PLA1) or A2 (PLA2) and subsequently these lysophos-
pholipids are hydrolyzed by plasma lysoPLD/ATX to produce LPA (Fig. 1C). Next to this route, 
LPA can be produced intracellularly as well, via phospholipid hydrolysis by an intracellular 
PLD and subsequent hydrolysis of the product phosphatidic acid (PA) by PA-selective PLA 
(Fig. 1D). However, intracellular LPA is thought to be an intermediate for the synthesis of 
more complex phospholipids and it is unlikely to function as an extracellular mediator (7). 
Extracellular Metabolism of LPA
LPA is a mixture of fatty acids that vary in the type of fatty acyl chain (length and saturation) 
and the linkage to the glycerol backbone (sn-1 or sn-2). LPA species with saturated fatty 
acids (16:0, 18:0) and unsaturated fatty acids (16:1, 18:1, 18:2, 20:4) have been detected in 
vivo (8). In serum and plasma, LPA is bound to albumin (9). While human plasma LPA levels 
are low (10;11), serum LPA levels are significantly higher (9;12). For this reason it has been 
proposed that LPA in serum is produced by platelets as a result of blood coagulation. It is 
now clear that increased serum LPA levels upon platelet activation are not due to secretion 
of LPA from platelet granules. Instead, LPA is generated de novo by sequential actions of 
phospholipases. First, lysophospholipids (mainly LPC) are produced by activated platelets 
via PLAs and subsequently these lysophospholipids are hydrolyzed by ATX to produce LPA 
(13;14). In addition, LPA can be produced by hydrolysis of either PA, released by platelets, or 
LPC that is present on erythrocyte membranes. However, these two pathways make minor 
contributions to LPA production in blood (13).  
Steady-state plasma LPC levels (>100 mM) are about 1000-fold higher than the levels of 
LPA, while ATX is constitutively active (12-14). This suggests a tightly controlled equilibrium 
between production, degradation and clearance. Indeed, LPA is rapidly degraded by mem-
brane-bound phosphatases, mainly lipid phosphate phosphohydrolase type 1 (15), and ATX 
is cleared from the circulation within minutes (16). Moreover, the low plasma LPA levels 
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Figure 1: Structure and production of LPA. (A) Chemical structure of 1-acyl-2-hydroxy-sn-glycero-3-phosphate 
(LPA). In this example 1-oleoyl LPA (LPA 18:1) is shown. Note the presence of the fatty acyl chain on the 
sn-1 position of the glycerol backbone, which is the most common form. (B) Chemical structure of 1-oleo-
yl-2-hydroxy-sn-glycero-3-phosphocholine (LPC). In this example 1-oleoyl LPC (LPC 18:1) is shown. The red 
arrow depicts where LPC will be hydrolyzed by ATX. (C), (D) LPA is produced via two major pathways: an 
extracellular (C) and intracellular (D) route. Several LPA species can be produced via these pathways, de-
pending on the length and saturation level of the fatty acyl chain of the phospholipids. Note that phospho-
lipids contain two fatty acyl chains, while lysophospholipids only have a single fatty acyl chain. Examples 
of phospholipids are phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine, which all 













































suggest high capacity of peripheral tissues to take up or metabolize circulating LPA (17). To-
gether, these processes will  contribute to the maintenance of low levels of circulating LPA. 
LPA Receptors
LPA evokes a wide variety of cellular responses through binding to specific type I, rhodop-
sin-like G protein-coupled receptors (GPCRs), which are seven-transmembrane cell-surface 
receptors that signal via heterotrimeric G proteins. Subsequently, these G proteins can acti-
vate multiple signaling cascades (18). Until now, six LPA receptors have been identified and 
termed LPA1-6, which can be subdivided into two subfamilies (Fig. 2A). The presence of two 
LPA receptor subfamilies suggests that LPA receptors have evolved from distinct ancestor 
genes. LPA1-3 belong to the “endothelial differentiation gene” (EDG) family and show about 
50% amino acid homology. They are the “classical” LPA receptors and were formerly called 
EDG-2, EDG-4, EDG-7 respectively. The five additional members of the EDG-receptor sub-
family are receptors specific for the bioactive lysophospholipid S1P, a small lipid similar to 
LPA but with a sphingosine instead of a glycerol backbone. The newly identified LPA recep-
tors LPA4-6 (or P2Y9, GPR92, P2Y5, respectively) are more closely related to the purinergic 
(P2Y) receptors, sharing about 35% amino acid identity. They were previously thought to 
bind nucleotides like their purinergic receptor family members (19;20). 
Biological Effects of LPA
LPA signaling through GPCRs activates a wide variety of signaling pathways, ranging from 
cell proliferation and migration to neurite remodeling and cytokine production (21;22). The 
effects include developmental and (patho) physiological processes and they involve basic 
cellular responses as well as multiple organ systems. LPA receptors show both overlapping 
and distinct signaling properties and tissue expression, with an outcome of LPA signaling 
depending on the LPA receptor expression profile in the cell (19;20). Some of the major 
biological effects of LPA are summarized in Table 1. 
The main LPA-induced signaling pathways and there downstream effects are shown in 
Fig. 2B. They include: (i) cell proliferation via the Gi-linked Ras-MAPK (mitogen-activated 
protein kinase) pathway (23;24); (ii) cell survival via Gi-mediated activation of both the PI3K 
(phosphatidylinositol 3-kinase) - Akt/PKB (protein kinase B) pathway and the MAPK pathway 
(25;26); (iii) cytoskeletal remodeling and cell migration via the G12/13-RhoA pathway (27;28) 
and Gi-mediated Rac activation (29); (iiii) Gq-mediated hydrolysis of PIP2 (phosphatidylino-
sitol-bisphosphate) by PLC (phospholipase C), with consequent calcium mobilization and 
PKC (protein kinase C) activation (30;31). Furthermore, LPA stimulation can induce changes 
in  cAMP (cyclic adenosine monophosphate) levels via Gi or Gβγ subunits and production of 
growth factors and cytokines (reviewed in (19)). 
AUTOTAXIN
ATX was identified as an autocrine motility factor from A2058 melanoma cell-conditioned 
medium about two decades ago (32). Its mode of action was a mystery at the time and 
it took another decade until it was discovered that ATX was identical to plasma lysoPLD, 
responsible for the production of LPA (2;3). ATX, or NPP2, is a member of the ecto-nucleo-
tide pyrophosphatase/phosphodiesterase ((E)NPP) family, consisting of seven structurally 
related ecto-enzymes. NPPs are usually present at the cell surface as type-I or type-II trans-
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membrane proteins and are known to hydrolyze pyrophosphate or phosphodiester bonds 
in nucleotides and their derivatives. Despite their structurally related catalytic domain, each 
NPP enzyme has well-defined substrate specificity. Currently, it is widely accepted that ATX, 
although capable of hydrolyzing nucleotides in vitro, primarily functions as a lysoPLD in 
vivo and thus represents a unique family member. The closest relatives of ATX, NPP1 and 
Figure 2: LPA receptor signaling. (A) Phylogenetic tree of human LPA receptors with indicated amino acid 
identity to LPA1. The EDG family receptors are depicted in light grey and and the purinergic receptors in 
dark grey. This figure is adapted from (19). (B) Major signaling pathways of the LPA receptors, showing the 
distinct G proteins and their corresponding downstream effectors. G proteins are heterotrimeric proteins 
composed of 3 subunits: α, β and γ. RhoGEF: Rho-specific guanine nucleotide exchange factor. This figure 
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NPP3, convert adenosine triphosphate (ATP) into pyrophosphate (PPi) and thereby regulate 
mineralization and calcification in bone. NPP6, as well as NPP7, is a choline-specific 
ectophospholipase C, probably serving catabolic functions. Activities of NPP4 and NPP5 are 
currently not defined (33).  
ATX Processing
ATX is synthesized as a pre-pro-enzyme; the N-terminal signal peptide is removed by a 
signal peptidase, the protein is further trimmed by a furin-type protease, traffics along the 
classical export pathway and is subsequently secreted as an extracellular enzyme into the 
circulation (34-36). ATX is a heavily glycosylated protein and glycosylation of asparagine-
residue 524 (Asn524) is essential for catalytic activity (37). ATX has a rapid turnover; it is 
cleared from the circulation within minutes and subsequently degraded in the liver. The 
constant levels of ATX and LPA in serum suggest a continuous synthesis of ATX (16). The 
cellular source of plasma ATX remains to be identified, but it is likely to originate from the 
abundant ATX-expressing lymphatic high endothelial venules (38) and/or adipose tissue 
(39). Indeed, adipose-ATX contributes significantly (though not completely) to circulating 
LPA levels, as demonstrated in adipose-specific ATX knockout mice that show around 40% 








Cancer Tumor progression, inva-
sion and angiogenesis 
(80;88;89)
Pulmonary fibrosis Fibroblast recruitment 
and vascular leakage (75)
Nervous system Neurite retraction (90)
Growth cone collapse or 
turning (90) 
Ion channel activity (91)
Neuropathic pain Nerve demyelination and 
initiation of pain (74)
Vascular system Platelet activation and 
aggregation (92)
Vascular remodeling (93)
Stabilization of embryonic 
vessels (62;63)
Atherosclerosis Atherothrombogenesis in 
atherosclerotic plaques 
(94)
Cancer Stimulation of tumor 
angiogenesis (89)
Immune system Cytokine production (95)
Lymphocyte trafficking  
(38)
Atherosclerosis Induction of atheroscle-
rosis stimulating cytokine 
CXCL1 (96)
Adipose system Adipocyte proliferation 
and migration control (97)
Obesity Regulation of food intake 
(67)
Table 1: Major biological LPA signaling-mediated functions. Note that this list focuses on the main effects of LPA 
and is not complete. However, the remarkable diversity of effects points to the multifunctional signaling 




Expression of ATX is most abundant in brain, placenta, ovary and small intestine; while 
intermediate expression levels are detected in kidney, prostate, testis, pancreas, colon and 
lung (41). During mouse development, ATX is first detectable at embryonic day 8.5 (E8.5) 
in the extra-embryonic yolk sac and at E9.5 in the floor plate of the neural tube (42). At 
later embryonic stages and in adulthood, high ATX expression is observed in choroid plexus 
epithelium (35;42-44). ATX has been detected in biological fluids, like cerebrospinal fluid 
(35;45), seminal fluid (46) and ascites (47).  
Phosphodiesterase and LysoPLD Activity
ATX has both phosphodiesterase (PDE) and lysoPLD activity in vitro; it hydrolyzes nucleo-
tide and lysophospholipid substrates, respectively, with threonine-residue 210 (Thr210) as 
the catalytic center for both activities. The PDE activity of ATX, however, does not seem to 
be of biological importance, as the apparent affinity for LPC is much higher than that for 
nucleotides (48). ATX has also been shown to hydrolyze sphingosylphosphorylcholine (SPC) 
and produce S1P in vitro (49). However, physiological significance is ambiguous due to a 
thousand-fold higher Km of ATX for SPC than the normal SPC levels in plasma and serum (50). 
Thus, the biological roles of ATX are thought to be fully attributable to LPA production and 
subsequent signaling through LPA receptors.
ATX Crystal Structure
The recently obtained crystal structures of rat and mouse ATX identify a compact four 
domain-based architecture of two somatomedin B-like (SMB) domains, a central catalytic 
PDE domain and a nuclease-like (NUC) domain (Fig. 3A) (51;52). The PDE domain extensively 
interacts with the SMB-1 and SMB-2 domains on one side and with the NUC domain on the 
other side. A short loop is connecting the SMB and PDE domains and a long “lasso loop”, 
wrapped around the NUC domain, connects the PDE and NUC domains. The Asn524-linked 
glycan chain further reinforces the interdomain interactions, in agreement with the finding 
that this glycan is essential for catalytic activity (37). 
The catalytic domain of ATX is similar to that of the bacterial Xanthomonas axonopodis NPP, 
a structural and evolutionary relative to alkaline phosphatase (AP). The crystal structure of 
ATX reveals the presence of two catalytic zinc ions coordinated by conserved residues, in 
close proximity to Thr210. As in X. axonopodis NPP and many other enzymes, the ions in this 
conserved bimetallo site participate in bond-breaking steps (51;53).
The catalytically inactive NUC domain has been thought to be involved in substrate binding 
and presentation (54). It is now clear that the rigid PDE-NUC domain interface merely func-
tions to stabilize the thermodynamically unstable structure of the hydrophobic pocket of 
ATX, without directly contributing to the active site formation. Moreover, this stabilizing ef-
fect could be the reason why the hydrophobic lipid-binding pocket of ATX is always accessi-
ble, while most lipases have a closed pocket that only opens upon substrate binding (51;52). 
Substrate Specificity
ATX hydrolyzes both nucleotide and phospholipid substrates in vitro (48). Substrate discrimi-
nation of ATX and the diverse substrate preferences of NPP family members have been a 
long time mystery. The ATX crystal structure reveals that both nucleotides and lipids partially 
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Figure 3: The structure of ATX. (A) The upper panel shows the crystal structure of ATX bound to LPC 14:0 
with the N- and C-terminus, the zinc ions (yellow spheres) in the active site, the calcium ion (blue sphere) 
bound to the EF hand-like motif indicated. LPC, the essential glycan chain of Asn524, the integrin-inter-
action motifs LDV and His119 (close to the RGD motif) are depicted in a stick-and-sphere representation. 
The lower panel shows a schematic overview of the domain organization, with the active site residue 
Thr210, the 18-residue deletion (specific for ATX in the NPP family and responsible for formation of the 
lipid binding pocket) and Asn524 (containing the glycan chain essential for interdomain interactions be-
tween PDE and NUC). This figure was prepared using Pymol (www.pymol.org), adapted from (58). (B) 
Surface representation of ATX bound to LPC 14:0, with the acyl chain pointing into the viewing plane and 
the tunnel pointing upwards (left panel). LPC is shown in a sphere model. Domain colors are the same as 
in Fig. 3A. The right panel shows a zoom-in on the ATX active site showing LPA in the tunnel (again pointing 
upwards), which forms a T-junction with the substrate binding pocket containing LPC (with the phosphate 
group bound to the active site in the lower right corner and the acyl chain pointing inwards). The roof of 
the tunnel is partially made by residues of the SMB-1 domain, depicted in purple. This figure was prepared 
using Pymol (www.pymol.org), adapted from (58).




















share the same binding pocket. The acyl chain of lipid substrates form additional hydropho-
bic contacts with ATX, suggesting that the product LPA has a higher affinity for ATX than nu-
cleotide substrates and can only be displaced by lysophospholipid substrates like LPC. This 
would explain why LPA acts as an inhibitor of ATX activity against various artificial substrates 
(36) but not of LPC hydrolysis (55), determining LPA as a “substrate-specifying factor” (51). 
The presence of an 18 amino acid insertion loop in all of the NPP family members, except 
ATX, is a major determinant for substrate specificity among the family. This insertion loop 
blocks the entry of the hydrophobic binding pocket, suggesting that the hydrophobic pocket 
is an extension of the nucleotide binding site. The absence of the loop in ATX enables the 
enzyme to accept both nucleotides and lysophospholipids as a substrate and to use the 
same catalytic site for both activities. Moreover, this pocket can only accommodate mono-
acyl but not diacyl phospholipids, providing substrate specificity for phospholipids with a 
single acyl chain and with an optimal length of 14 carbons (51;52). 
Close to the hydrophobic pocket of ATX is a narrow tunnel, which is formed by the PDE and 
SMB-1 domains (Fig. 3B). An SMB-deletion mutant of ATX is ten-fold less sensitive to LPA 
inhibition, suggesting a role for the SMB domain and the tunnel in substrate recognition 
or product release (51). Indeed, Nishimasu and colleagues imply the presence of LPA in 
this hydrophobic tunnel, which suggests that the tunnel could function as a product exit 
route. Again, due to the presence of the insertion loop, the other NPP family members lack 
this tunnel. Another option would be that the tunnel serves as an entrance site for LPC 
substrates released from cells, which could function as a shuttle mechanism for substrate 
entrance versus product release to deliver LPA directly to LPA receptors on the cell mem-
brane (52).
ATX Interactions
ATX has a flat molecular surface on the side of the tunnel, which is suggested to function 
as a cell membrane-binding platform to provide LPA directly to its receptors (52). Next to 
this model of direct binding, ATX has been suggested to bind to cells via interaction with 
integrins. T cells are able to interact with ATX in an integrin α4β1-dependent manner, sugges-
ting a model in which secretion of ATX and subsequent localized LPA production promotes 
lymphocyte motility. This interaction is thought to involve a Leu-Asp-Val (LDV) integrin- 
binding motif on the surface of the PDE domain of ATX (38). In addition to lymphocytes, ATX 
can bind to activated platelets in an integrin β3-dependent manner, which could be medi-
ated by an Arg-Gly-Asp (RGD) sequence motif present in ATX (56).
The ATX crystal structure revealed that the SMB domains are the primary mediators 
of the β3-mediated ATX-integrin interaction. However, the binding mode is structurally 
distinct from the classical RGD-mediated integrin binding and involves a wider portion of 
the surface of the SMB-2 domain (51). Recently, platelets have been shown to bind ATX in 
an integrin-dependent manner with subsequent increase in local LPA production. Moreover, 
it is suggested that this ATX-integrin interaction even enhances LPA production, possibly by 
reorientation of the SMB domains to speed up catalysis or product release (57). Next to 
interactions with integrins, ATX is able to bind heparin. In chapter 5 we discuss our latest 
insight in ATX-heparin interactions and propose a third mechanism of localized LPA signa-
ling by sequestering ATX to target cells via heparin sulphate proteoglycans. Together, these 
18
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models of ATX recruitment to the cell surface suggest that ATX not only drives the produc-
tion of LPA, but also guides specificity of LPA signaling. Alternatively, the function of these 
interactions could be non-catalytic signaling of ATX via integrins (58).
ATX Isoforms
The human gene encoding ATX, ENPP2, is located on chromosome 8 and is organized in 
27 exons. Alternative splicing of the ENPP2 gene gives rise to three isoforms; ATXα, ATXβ 
and ATXγ. The originally isolated ATX isoform termed “autocrine motility factor”, cloned 
from A2058 melanoma cells, was called ATX-melanoma or ATXα (32;59). Later, ATX-terato-
carcinoma (ATXβ) was cloned from a teratocarcinoma cell line (41). This isoform is identical 
to plasma lysoPLD and currently the most widely studied isoform. A third, brain-specific 
isoform PD-Iα was identified and termed ATXγ (44;60). The ATXα and ATXγ isoform are 
characterized by the presence of exon 12 and 21, respectively. ATXα represents the longest 
isoform with a 52 amino acid insert in the PDE domain. ATXγ has an insert of 25 amino acids 
in the NUC domain. ATXβ was thought to be the shortest isoform, lacking both exon 12 and 
21. Recently, two new isoforms have been identified: ATXδ and ATXε. ATXδ has a deletion 
of 4 amino acids in the lasso loop and ATXε is characterized by the 52 amino acid insert 
encoded by exon 12 together with the 4 amino acid deletion. Of all isoforms, ATXα repre-
sents the longest isoform and ATXδ the shortest (Fig. 4). ATXβ and ATXδ seem to be vastly 
expressed, ATXγ moderately, while ATXα and ATXε are much less abundant (61). The ATXα 
isoform is of special interest, since it contains a large insert in the heart of the catalytic do-
main. The unique biochemical properties of the ATXα isoform will be discussed in chapter 5. 
ATX-LPA RECEPTOR SIGNALING IN DEVELOPMENT
ATX Knockout Mice
Gene targeting studies in mice show a crucial role for ATX in embryogenesis. Enpp2 deficien-
cy causes embryonic lethality at E9.5 due to vascular defects in both yolk sac and embryo. 
The vascular network normally present in the yolk sac is completely absent and replaced by 
blood patches, blood vessels in the embryo are enlarged and the neural tube is malformed. 
Figure 4: ATX isoforms. Protein structure of the five known isoforms of ATX ordered by length, with the long-
est isoform (ATXα) containing 915 residues and the shortest isoform (ATXδ) comprising 859 residues. The 
ATXα and ATXε isoforms are characterized by a 52 residue insert in the PDE domain (encoded by exon 12), 
ATXγ by a 25 residue insert in the NUC domain (encoded by exon 21), ATXδ and ATXε by a deletion of the 
first 4 amino acids of exon 19 in the lasso loop. ATXα, ATXβ and ATXγ all contain an intact exon 19. The 
domain architecture is depicted on top. This figure was adapted from (61).













Moreover, the heterozygous mice show half-normal plasma LPA levels, indicating that ATX 
is the main enzyme producing LPA in the circulation (62-64). Transgenic mice expressing 
the inactive mutant ATX-T210A display the same lethal phenotype, confirming that catalytic 
activity of ATX is crucial for vascular development (65).
LPA Receptor Knockout Mice
Loss of LPA1 in mice results in 50% neonatal lethality and a reduced body size of surviv-
ing pups (66), which was attributed to defective suckling but has now been shown to be 
caused by a reduced food intake as well (67). In addition, LPA1 has been implicated in neuro-
genesis, as a specific variant of the Lpa1 KO strain shows defects in cortical development 
(68). Lpa2 knockout mice are viable and without any phenotypic abnormalities, while 
Lpa1 /Lpa2 double knockout mice do not show additional phenotypic abnormalities next to 
the defects found in the Lpa1 single knockout mice. Thus, LPA2 is not essential for mouse 
development, but rather acts redundantly with LPA1 (69). 
LPA3 signaling, though, is crucial for embryo implantation and spacing. While Lpa3 knockout 
mice appear normal, the Lpa3-deficient females show a reduced litter size due to delayed 
embryo implantation and embryo crowding (70). Lpa1 /Lpa2 /Lpa3 triple knockout mice show 
defects in male reproductive function, next to the phenotypes consistent with single re-
ceptor deletants (71). Lpa4-deficient mice display abnormalities in the blood and lymphatic 
vascular system, causing partial lethality of embryos and newborn pups (72). The latter phe-
notype shows some similarities to, but is less severe than the Enpp2 knockout mice. 
ATX-LPA Receptor Signaling in Vascular Development
The vascular defects observed in Enpp2-deficient embryos have also been found in G13 
knockout mice (73). Absence of G13 does not influence the formation of endothelial cells, 
but affects the growth and sprouting of endothelial cells to form an organized vascular net-
work (73). While initial blood vessel formation is not affected in the Enpp2 deficient mice, 
newly formed blood vessels fail to mature in the absence of ATX (62;63). This suggests that 
ATX and LPA play a role in angiogenesis. However, ATX and LPA are suggested to function 
in stabilizing preformed blood vessels, rather than being angiogenic factors (63). Thus, loss 
of LPA-G13 signaling is likely to underlie the vascular defects of Enpp2 knockout embryos, in 
particular defects in the formation and stabilization of blood vessels. 
ATX-LPA RECEPTOR SIGNALING IN (PATHO)PHYSIOLOGY
ATX-LPA signaling has been implicated in a wide range of physiological and pathological 
processes, ranging from vascular and neural development (62-64), lymphocyte trafficking 
(38), neuropathic pain (74), fibrosis (75), hydrocephalus (76) and cholestatic pruritis (77) to 
tumor initiation and progression (78-81). ATX may function as a potential diagnostic marker 
since the serum or plasma levels are increased in some physiological and pathological con-
ditions like chronic liver disease (82), obesity (39;40), cancer (83) and pregnancy (84). In 
addition, the implication of the ATX-LPA axis in diverse pathophysiological processes has 
put forward the identification of ATX as a valuable therapeutic target. The crystal structure 
has revealed a wealth of important information regarding substrate binding and selectivity, 
which will boost the design and optimization of effective ATX inhibitors in the near future. 
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A prominent area of research interest is the emerging role of ATX-LPA receptor signaling 
in cancer. With its growth-factor like activities, LPA stimulates multiple signaling pathways 
that could contribute to tumor initiation and progression as well as metastasis. Indeed, LPA 
receptor expression and signaling, aberrant LPA production and ATX expression have all 
been linked to cancer (1). As discussed above, most evidence is pointing to a role of the 
ATX-LPA signaling axis in vivo in the vascular system.  This raises the question if ATX could 
contribute to the progression of tumors by stabilizing blood vessels in tumors or the tumor 
microenvironment, in addition to its effect on proliferation and migration. Additional studies 
such as deletion of non-EDG LPA receptors (LPA4-6) and their combinations, as well as tissue 
specific or inducible deletion of both ATX and/or LPA receptors, are awaited to sort out the 
mechanism of the ATX-LPA signaling axis and its role in development and pathology. Details 
about the role of ATX-LPA receptor signaling in cancer will be further discussed in chapter 2.
THESIS OUTLINE
The ATX-LPA receptor axis has a wide implication in health and disease. The studies 
described in this thesis focus on the biochemical and functional properties of ATX to 
increase our understanding of its molecular actions. Chapter 2 reviews the latest insights of 
ATX and LPA receptor signaling in cancer. The prognostic value of ATX protein expression in 
breast cancer is explored in chapter 3. Chapter 4 describes the development and optimiza-
tion of a first-generation ATX activity-based probe for in vivo screening of ATX activity. Next, 
the specific characteristics of the ATXα isoform have been studied: intradomain cleavage of 
ATXα and high-affinity binding to heparin are discussed in chapter 5, and the SH3 domain-
mediated protein-interaction capacity of ATXα is described in the chapter 6. In chapter 7, all 
results presented in this thesis are summarized and discussed. 
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ABSTRACT
Lysophosphatidic acid (LPA; monoacyl-glycerol-3-phos-
phate) is a lipid mediator that functions as a mitogen and 
motility factor for many cell types. LPA signals through six 
specific G protein-coupled receptors, named LPA1–6, which 
trigger both overlapping and distinct signaling pathways. 
LPA is produced from extracellular lysophosphatidyl-
choline by a secreted lysophospholipase D, named auto-
taxin (ATX), originally identified as an “autocrine motility 
factor” for tumor cells. ATX-LPA signaling is vital for 
embryonic development and promotes tumor forma-
tion, angiogenesis, and experimental metastasis in mice. 
Elevated expression of ATX and/or aberrant expression of 
LPA receptors are found in several human malignancies, 
while loss of LPA6 function has been implicated in bladder 
cancer. In this review, we summarize our present under-
standing of ATX and LPA receptor signaling in cancer.
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INTRODUCTION
The impact of the tumor microenvironment on tumor progression is mediated, in large 
part, by growth factors, motility factors and proangiogenic factors that are produced by the 
tumor cells themselves as well as the surrounding stroma. One such factor is lyso- 
phosphatidic acid (LPA; monoacyl-glycerol-3-phosphate), a multifunctional lipid media-
tor best known for its ability to stimulate proliferation, migration and survival of many cell 
types, both normal and malignant. However, the list of biological responses to LPA is quite 
diverse, as it ranges from growth factor-like activities to neurite remodeling and modulation 
of ion channel activity (1;2). Bioactive LPA is produced extracellularly from lysophospha-
tidylcholine (LPC, an abundant plasma lipid) by a secreted lysophospholipase D (lysoPLD) 
(3;4), known as  autotaxin (ATX), named after its first discovered activity as an “autocrine 
motility factor” for melanoma cells (5). LPA acts through six known G protein-coupled recep-
tors (GPCRs), termed LPA1-6, which are differentially expressed and show both overlapping 
and distinct signaling properties (1;6). A schematic representation of the ATX-LPA receptor 
signaling axis is shown in Fig. 1.
Fig. 1. Autotaxin-LPA receptor signaling. Autotaxin is a secreted lysophospholipase D  that hydrolyzes extra-
cellular LPC (an abundant plasma phospholipid) into bioactive LPA. LPA acts through specific G protein-
coupled receptors and stimulates cell proliferation, migration, and survival. ATX is a multidomain enzyme; 



























Increasing evidence points to an important role for ATX and LPA receptor signaling in cancer 
(7), as will be discussed below. In brief: (1) elevated or aberrant expression of ATX and LPA 
receptors is found in several human malignancies; (2) overexpression of ATX or individual 
LPA receptors promotes tumor formation and metastasis in mouse models, whereas knock-
down has the opposite effect; and (3) LPA2 knockout mice show reduced colon carcino-
genesis. Moreover, loss of function of LPA6 has been implicated in bladder cancer develop-
ment, suggesting that LPA6 is a candidate tumor suppressor. In this review, we summarize 
the evidence for a role of ATX-LPA signaling in cancer and also discuss recent developments 
in targeting ATX by pharmacological inhibitors. 
LPA RECEPTOR SIGNALING 
LPA receptors can be divided in two subfamilies. The classical LPA1-3 receptors belong to the 
so-called endothelial differentiation gene (Edg) family, whereas three additional LPA recep-
tors (LPA4-6) are more closely related to the purinergic receptor family (1;6). Depending on 
receptor subtype, LPA stimulation results in: (1) activation of the mitogenic Gαi-linked Ras-
Raf-MEK-ERK pathway (8;9), (2) Gαi-mediated activation of phosphoinositide 3-kinase-beta 
(10), which promotes cell survival and many other cellular functions, (3) cytoskeletal remo-
deling, cell migration and invasion via the Gα12/13-linked RhoA pathway acting in concert with 
the Gαi-mediated Rac activation pathway (11-13); and (4) Gαq-linked activation of phos-
pholipase C with consequent production of second messengers (14;15). In addition, LPA 
stimulation often leads to changes in cAMP levels via either Gαi or Gβγ subunits (for review, 
see (1;2)). LPA stimulation also promotes the production of growth factors and cytokines 
via multiple pathways (16). For a given LPA receptor, the net outcome of these synergizing 
signaling pathways strongly depends on cellular context. For example, depending on the 
cell system used, LPA4 receptor signaling may either enhance (17) or inhibit (18) tumor cell 
migration and invasiveness. 
LPA PRODUCTION BY AUTOTAXIN, A SECRETED LYSO-PLD
LPA is produced by autotaxin (ATX or ENPP2), a member of the ecto-nucleotide pyrophos-
phatase/phosphodiesterase (ENPP) family. The ENPP family consists of seven structurally re-
lated ectoenzymes that hydrolyze pyrophosphate and phosphodiester bonds in nucleotides 
and their derivatives (19). ATX hydrolyzes LPC into LPA (plus free choline) and is the only 
lysoPLD in the ENPP family. ATX is synthesized as a preproenzyme, processed by a furin-type 
protease and secreted along the classical secretory route as a glycosylated protein into the 
extracellular milieu (reviewed in (20)). ATX is widely expressed and present in plasma. The 
origin of plasma ATX remains to be determined, but likely sources are the lymphatic high 
endothelial venules (21) and adipose tissue, which express and secrete ATX at high levels. 
Indeed, adipose-specific deletion of Enpp2 leads to reduced plasma LPA levels (22).  
ATX is a multidomain protein consisting of two N-terminal somatomedin B (SMB)-like 
domains, a central catalytic phosphodiesterase domain, and an N-terminal nuclease-like 
domain (19;20). Although ATX is capable of hydrolyzing nucleotides in vitro, the  appar-
ent affinity of ATX for LPC is some 10-fold higher than for nucleotides (23) and, further-
more, extracellular nucleotide levels are normally very low. Therefore, all biological effects 
of ATX are thought to be attributable to LPA production and subsequent receptor stimula-
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tion (20). Formally, however, additional noncatalytic functions of ATX cannot be excluded at 
present. Recent structural studies (24;25) have revealed how the different domains of ATX are 
organized and interact (Fig. 1) and shed light on what makes ATX a unique lysoPLD, namely 
a deep hydrophobic lipid-binding pocket in the catalytic domain. The ATX structure further 
suggests that the SMB domains could be involved in regulating catalytic activity (24).  
ATX INTERACTION WITH THE CELL SURFACE 
To ensure efficient delivery of LPA to its receptors, ATX must communicate with target cells 
in a locally restricted manner. One mechanism by which ATX interacts with target cells is 
via integrins. ATX binds to activated lymphocytes via α4β1 integrins (21) and to activated 
platelets via integrin β3 (26). The SMB domains of ATX appear to be the primary mediators 
of integrin β3 binding (24). Injection of enzymatically inactive (“dominant-negative”) ATX in 
mice attenuates the homing of T cells to secondary lymphoid organs, presumably by com-
peting with endogenous ATX for binding to integrins (21). Since ATX is abundantly expressed 
in lymphatic high endothelial venules (HEVs), this suggests a model in which secretion of 
ATX by HEVs promotes the entry of lymphocytes into lymphoid organs. In this model, ATX 
is secreted into the lumen of HEVs and binds to adherent lymphocytes through activated 
integrins. Subsequently, the lymphocyte-bound ATX may produce a high local concentration 
of LPA to activate LPA receptors on the lymphocytes and promote their transendothelial 
migration (21). In support of this scenario, LPA induces invasion of T lymphoma cells across a 
monolayer of normal fibroblasts (12). Thus, ATX/LPA could use a similar strategy to stimulate 
the extravasation of circulating tumor cells, a hallmark of the metastatic cascade.  
Since ATX is a heparin-binding protein (as it can be purified using heparin affinity chroma-
tography), binding to heparan sulfate proteoglycans (HSPs) on the cell surface could be 
an alternative or additional way by which ATX ensures local delivery of LPA to its cognate 
receptors. Thus, diverse scenarios for localized LPA production and signaling can be envi-
sioned in which ATX is recruited to target cells via specific cell-surface molecules such as 
integrins and HSPs. 
ATX AND LPA RECEPTORS IN EMBRYONIC DEVELOPMENT
Gene targeting studies in mice have revealed a vital role for ATX during embryogenesis, as 
Enpp2 knockout causes embryonic lethality at midgestation (around E9.5) due to severe 
vascular defects in both yolk sac and the embryo proper (27;28). The vascular network 
normally present in the yolk sac is completely absent and replaced by blood patches, while 
blood vessels in the embryo are enlarged; furthermore, the neural tube is malformed 
(28;29). Heterozygous Enpp2 knockout mice show half-normal plasma LPA levels, consis-
tent with ATX being the major LPA-producing enzyme in the circulation. The phenotype of 
Enpp2-knockout mice is strongly reminiscent of that of the Gα13 knockout, suggesting that 
the observed defects in Enpp2-null embryos can be explained by loss of migratory G13-RhoA 
signaling through multiple LPA receptors (28;30).
The phenotype of individual LPA receptor knockouts is much less severe than that of the 
Enpp2 knockout. Thus far, LPA receptor knockout studies in mice have uncovered normal 
physiological roles for LPA signaling in such diverse processes as neurogenesis (31) and bone 
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formation (32) (LPA1), embryo implantation  (LPA3) (33), and formation of blood and lym-
phatic vessels (LPA4) (34). Lpa2-knockout mice show no abnormalities (35), while the Lpa5- 
and Lpa6-deficient phenotypes remain to be described.
ATX-LPA RECEPTOR SIGNALING IN CANCER         
Since the discovery of ATX as an autocrine motility factor for melanoma cells, many 
subsequent studies have implicated a role for ATX-LPA signaling in tumor formation and 
metastasis. 
Studies in vitro
High expression of ATX is found in a number of tumor cell types, including neuroblastoma 
(36), hepatocellular carcinoma (37), breast cancer (38), renal cell carcinoma (39), glioblas-
toma (40), non-small cell lung cancer (NSCLC) (41), B cell lymphomas (42;43), and thyroid 
carcinoma (44). Expression of ATX is found both in the tumor core as well as in the inva-
sive cells of glioblastomas (40), and in NSCLC the highest expression is detected in poorly 
differentiated tumors (41). This argues that ATX is able to augment cellular characteristics 
necessary for tumor aggressiveness.
ATX expression is regulated by various growth factors, cytokines, and (proto-)oncogenes, 
which will differ per cell type and thus cause diverse outcomes. For example, EGF, bFGF, 
TGFβ, and other factors induce up- or down-regulation of ATX mRNA depending on cell type 
(44;45). v-Jun-transformed fibroblasts show strongly upregulated ATX expression (46), while 
ATX is upregulated in Wilms’ tumors harboring oncogenic β-catenin mutations (47) and in 
mammary epithelial cells stimulated by Wnt-1 (48). Downregulation of ATX is observed fol-
lowing retinoic acid treatment of Wilms’ tumor cells and N-Myc-overexpressing neuroblas-
toma cells (49;50). 
In Hodgkin lymphoma cells, Epstein-Barr virus infection leads to strong induction of ATX 
expression, with subsequent generation of LPA and enhanced cell growth and survival (42). 
Specific downregulation of ATX decreased LPA levels and reduced cell growth and viability 
in these cells. Furthermore, ATX expression is strongly induced upon forced expression of 
integrin α6β4 in MDA-MB-435 tumor cells, an effect mediated by the transcription factor 
NFAT1 (51). This provides a possible explanation for the stimulatory effect of integrin α6β4 
on tumor cell migration and invasion. 
INSIGHTS FROM MOUSE STUDIES
Xenograft models
The first evidence for a tumorigenic role of ATX in vivo came from studies using ATX-over-
expressing, Ras-transformed NIH3T3 cells. ATX overexpression resulted in increased tumor 
growth, aggressiveness, and angiogenesis, whereas the inactive mutant ATX(T210A) did not 
(45;52). Subsequent studies have shown a role for both ATX and LPA receptor signaling in 
tumor progression and metastasis. LPA1 overexpression in MDA-MB-231 breast cancer cells 
promotes increased skeletal tumor growth and tumor-induced bone destruction in xeno-
grafted mice. The tumor cells do not express ATX, but they stimulate the production of LPA 
by activated platelets, thereby promoting tumor cell proliferation and cytokine-mediated 
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bone destruction (53). Silencing or pharmacological inhibition of LPA1 reduced both tumor 
growth and bone metastasis progression (54). Furthermore, ATX overexpression in mam-
mary carcinoma cells promotes metastasis to bone, while silencing of endogenous ATX 
expression inhibited metastasis, with little effect on primary tumor growth (55).  
Forced overexpression of LPA1, LPA2, or LPA3 in ovarian cancer cells enhances tumor growth 
in nude mice, showing increased growth factor production, ascites formation, and organ 
invasion (56). In another study, overexpressed LPA1, LPA2, and LPA4  were found to collabo-
rate with c-Myc and Tbx2 (a transcriptional repressor of p19Arf) to transform mouse embryo 
fibroblasts (MEFs) both in vitro and in xenografts. In this case, LPA-mediated cell transforma-
tion is mediated by the Gi-linked MAPK and PI3K pathways. Overexpression of individual LPA 
receptors in naïve MEFs had no transforming effect, indicating that LPA signaling needs to 
collaborate with other pro-oncogenic events to induce cell transformation (57).
Genetic models
Unfortunately, the embryonic lethality of Enpp2-deficient mice has hampered studies on 
the importance of ATX in cancer progression. However, important insights have been gained 
from studies in transgenic and LPA receptor-knockout mice. MMTV-driven overexpression 
of ATX or individual LPA receptors (LPA1-3) in mouse mammary gland leads to late-onset 
invasive and metastatic mammary carcinomas and cancer-associated inflammation. The 
transgene expression influenced several signaling pathways, including PI3K-Akt and MAPK 
pathways, as well as Wnt pathway components and E-cadherin. The ATX and LPA receptor-
driven tumors do not form a distinct cluster, as would be expected due to the fact that each 
of the receptors links to particular pathways and functional outcomes (58). This reinforces 
the notion that transgenic overexpression of ATX and LPA receptors allows accumulation of 
secondary mutations leading to mammary cancers, possibly by increasing cell viability upon 
LPA signaling and thus increasing the likelihood of acquiring (pro-)oncogenic mutations. 
Of the known LPA receptors, LPA2 has been implicated in intestinal cancer. In a model of 
chemically induced colon carcinogenesis, Lpa2-knockout mice (which show a wild-type 
phenotype) display a remarkably reduced tumor incidence and progression. This is 
accompanied by a decrease in both cell proliferation and chemokine expression, in particu-
lar the proinflammatory factors MCP-1 and MIF which are associated with colorectal cancer. 
Reduced colon tumorigenesis in the Lpa2-null animals correlated with reduced infiltration by 
macrophages, a predominant stromal cell type known to contribute to tumor progression. 
Furthermore, LPA treatment increased tumor incidence in Apcmin/+ mice, a model for sponta-
neous intestinal cancer (59). Conversely, loss of LPA2 dramatically reduced tumor incidence 
in Apcmin/+ mice, accompanied by reduced expression levels of cell cycle regulators such as 
KLF5, c-Myc and cyclin D1 (60). These studies show that LPA2, in combination with loss of the 
tumor suppressor APC, is capable of promoting tumorigenesis in the colon. It thus appears 
that, again, LPA signaling increases the susceptibility to accelerate cancer progression when 
other genetic factors are present. The results from the various in vivo studies are summa-
rized in Table 1. 
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Table 1. In vivo ATX and LPA receptor cancer models.
CLINICAL IMPLICATIONS
To what extent do the findings obtained in mouse models bear relevance to the human 
disease?  Cancer-specific gain-of-function mutations in ATX or LPA receptors have not been 
reported to date; in contrast, loss-of-function mutations have been reported for LPA6 in 
bladder cancer (see below). Analysis of multiple microarray datasets (www.oncomine.org) 
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reveals strongly elevated ATX expression in certain human cancers, especially B cell lym-
phomas, renal carcinoma, liver cancer, and pancreatic cancer. Also, individual LPA receptors 
are found overexpressed in several cancers when compared to the corresponding normal 
tissues (www.oncomine.org, see also (7)). 
In follicular lymphoma, serum ATX levels correlate with tumor burden and clinical course, 
suggesting that ATX may serve as a biomarker in follicular lymphoma (43). Furthermore, 
an increase in serum ATX activity has been reported in pancreatic cancer patients (61) and 
ENPP2 is one of the genes in a 64-gene signature that predicts poor survival of patients with 
stage I NSCLC (62). As a word of caution, it should be realized that high ATX expression by 
itself does not necessarily imply elevated LPA levels and enhanced receptor signaling, since 
substrate (LPC) availability and LPA degradation by cell-associated lipid phosphate phospha-
tases are additional determinants of bioactive LPA levels in the cellular microenvironment 
(20). Ultimately, it is the LPA receptor expression profile on both the tumor and surroun- 
ding stromal cells that will determine the outcome of enhanced ATX expression. One area of 
future research is to establish to what extent aberrant ATX and/or LPA receptor expression 
patterns are associated with clinical outcome.
LPA6: a candidate tumor suppressor in bladder cancer
The LPA6 receptor, previously known as orphan receptor P2Y5 (or 6H1), deserves special 
mention because it has been associated with familial bladder cancer (63) as well as ge-
netic hair growth abnormalities (64). LPA6/P2Y5 is known to couple to the G13-RhoA signal-
ing pathway, which regulates the actin cytoskeleton, but it does not mediate changes in 
cytosolic calcium or cAMP (65). P2RY5 is an inducible gene: its expression is rapidly induced 
upon T cell activation (66) and in LPA-stimulated fibroblasts (16).
The LPA6-encoding gene, P2RY5, is located inside the retinoblastoma tumor suppressor 
gene RB1 (intron 17) in the reverse orientation. In bladder cancer, a segment around RB1 is 
characterized by a loss of polymorphism associated with the initial expansion of neoplasia 
(63;67). This segment contains several so-called forerunner genes that may contribute to 
such expansion, and P2RY5 is one of these genes. Homozygous mutational inactivation of 
P2RY5 precedes the loss of RB during tumor development, while nucleotide substitutions 
in P2RY5 represent a cancer-predisposing factor, particularly in combination with tobacco 
smoking (63;67). Reintroduction of P2RY5 into bladder cancer cells that lacked it resulted 
in cell cycle arrest and apoptosis, consistent with P2RY5 being a candidate tumor suppres-
sor. One family with an inherited risk of cancer, including breast, colon, lung, prostate, and 
uterus, carried a germline mutation in P2RY5. The most frequent polymorphism results in 
a W307C mutation in the LPA6 cytoplasmic tail. This could affect LPA6 interaction with G 
proteins (63;67) and hence compromise LPA signaling, but this needs to be tested. Interest-
ingly, a single nucleotide polymorphism within the same genomic locus that is predicted 
to downregulate P2RY5 expression is a potential risk factor for developing invasive ovarian 
cancer (68).    
Loss of P2RY5 function has also been implicated in genetic hair growth disorders (64). LPA6 
is detected in the inner root sheath of hair follicles. However, human hair follicles do not 
express ATX but, instead, an LPA-producing phospholipase A1 encoded by LIPH (69); muta-
tions in LIPH induce the same abnormal hair growth phenotype as mutations in LPA6. This 
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raises the question of whether LPA6 in other tissues, such as bladder epithelium, is normally 
stimulated via ATX- or LIPH-mediated LPA production. Given the very restricted tissue distri-
bution of LIPH, however, ATX is the more attractive candidate. In conclusion, LPA6 provides 
a new paradigm for cancer development and may represent an early detection and risk 
marker in bladder cancer (70). It is now important that the biological function and signaling 
properties of LPA6 and its mutant versions be elucidated in further detail.
ATX AS DRUG TARGET
As a secreted phosphodiesterase, ATX is an attractive and easily “druggable” therapeutic tar-
get. Several ATX inhibitors have been based on the seminal finding that LPA and sphingosine 
1-phosphate (S1P) inhibits ATX activity against nucleotides and artificial substrates (Ki about 
100 nM) (23). Several LPA analogs have been described as ATX inhibitors, some with an 
effect on melanoma cell metastasis (71;72) and breast tumor growth in mice (73). Yet, 
the potency of LPA analogs is rather low (and even very poor when tested in ATX-medi-
ated LPC hydrolysis assays), and it is not clear whether the reported in vivo effects are 
attributable to ATX inhibition. Most LPA-based ATX inhibitors lack an in vivo pharmacodyna-
mic proof of principle in that they have not shown to lower circulating LPA levels. Furthermore, 
there are concerns about their potential agonistic effect on LPA receptors. FTY720, a struc-
tural analogue of sphingosine, is an immunomodulator for patients with relapsing multiple 
sclerosis. The active form, FTY720-phosphate (FTY-P) is an S1P mimetic and acts on S1P 
receptors with high potency. At higher concentrations, FTY-P (like S1P) is a competitive 
inhibitor of ATX and reduces plasma LPA levels when injected into mice (74). It remains 
to be seen, however, whether ATX inhibition underlies the reported anticancer effects of 
high doses FTY720 (74). Lipid phosphonate analogs that inhibit ATX activity against artificial 
substrates show a reducing effect on plasma LPA levels and B16 melanoma metastasis; how-
ever, their potency is relatively low (75).
Nonlipid, small-molecule inhibitors clearly hold more promise. High-throughput screening 
identified thiazolidinedione-based compounds as a new class of ATX inhibitors (76). Their 
potency is increased dramatically by introduction of a boronic acid moiety, designed to 
target the catalytic Thr residue in ATX. The most potent analogs show IC50 values <10 nM in 
LPC hydrolysis assays. Injection of these compounds into mice results in a rapid fall in circu-
lating LPA levels, consistent with LPA being rapidly produced and degraded in vivo (76;77). 
The crystal structure of ATX in complex with a boronic acid inhibitor reveals that it forms 
a reversibly covalent bond with the Thr210 nucleophile in the hydrophobic lipid-binding 
pocket of ATX (24). Another small-molecule inhibitor of ATX, PF-8380, shows adequate oral 
bioavailability and in vivo potency in reducing LPA levels in plasma and at sites of inflam-
mation, indicating that ATX is a major source of LPA during inflammation. Furthermore, a 
close pharmacokinetic/pharmacodynamic relationship was observed (78). Compounds like 
PF-8380 and thiazolidinediones can serve as useful tools for elucidating the role of ATX in 
tumor progression in mice.
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CONCLUDING REMARKS
Given its mitogenic and chemotactic properties, together with the wide distribution of LPA 
receptors, it is not surprising that LPA, when produced in the tumor-stroma microenviron-
ment, can enhance cancer progression. Although the clinical consequences of enhanced or 
aberrant LPA production and signaling remain to be determined, studies in mice have pro-
vided strong evidence that the ATX-LPA receptor signaling axis contributes to tumor forma-
tion, angiogenesis, and metastasis. The in vivo studies also indicate that distinct oncogenic 
events, such as H-Ras or c-Myc activation, must collaborate with LPA signaling to promote 
tumor progression. The LPA2 receptor provides perhaps the strongest case for a link between 
LPA signaling and cancer, since Lpa2-knockout mice show a marked decrease in colon tumor 
incidence. Additional evidence is provided by the study on transgenic overexpression of ATX 
and LPA receptors in mouse mammary gland. To more broadly assess the importance of LPA 
signaling in tumor maintenance and progression, a logical approach would be to crossbreed 
LPA receptor-null mice with genetically engineered mouse tumor models, in which cancer is 
initiated by Cre-recombinase-mediated activation of oncogenic mutations in specific tissues. 
The LPA6 receptor represents an interesting case, since it may function as a tumor sup-
pressor in familial bladder cancer and loss of function mutations have been detected in 
patients; nucleotide substitutions in the LPA6-encoding gene (P2RY5) are considered a cancer-
predisposing factor. Obviously, these intriguing findings require further validation and inves-
tigation. Lpa6 knockout mice will provide a powerful tool to examine the suspected tumor-
suppressing function of LPA6.
Hopefully, the knowledge on ATX-LPA signaling gleaned in academic labs can now be 
applied toward the development of new drugs for cancer treatment in the foreseeable 
future. That ATX is an extracellular enzyme and GPCRs, such as those for LPA, are highly 
druggable will add to their attractiveness as targets. Potent small-molecule inhibitors that 
target ATX in vivo have already been described. Now that the crystal structure of ATX has 
been determined, drug development efforts will undoubtedly get a further boost.
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ABSTRACT
Autotaxin (ATX) is a secreted phosphodiesterase that 
produces the lipid mediator LPA, a mitogen and motility 
factor for many cell types. ATX is essential for embryonic 
development, while excessive ATX-LPA signaling promotes 
tumor formation, angiogenesis and experimental metas-
tasis. In particular, overexpression of ATX in mouse mam-
mary glands promotes late-onset, invasive mammary 
cancer. However, little is known about ATX expression in 
human breast cancer. Here, ATX immunohistochemistry 
was performed in 193 breast cancer samples, and as-
sociations between ATX expression, clinico-pathological 
characteristics and survival were evaluated. Virtually 
all carcinoma samples were ATX-positive, regardless of 
tumor size, grade or lymph node status, while the 
surrounding stroma showed little or no ATX expression. 
Despite the high amount of ATX-immunoreactivity, there 
was no significant correlation between ATX protein and 
mRNA expression and clinical parameters. We conclude 
that, although breast cancer cells express ATX and are 
known to be LPA-responsive, the ATX expression profile by 
itself is not significantly correlated with clinical outcome.
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INTRODUCTION
Lysophosphatidic acid (LPA) signaling is implicated in both physiological as well as 
pathological processes by inducing proliferation, migration and many other cellular func-
tions (reviewed in (1)). LPA acts on specific G protein-coupled receptors, which are 
expressed in virtually every cell type (2). Autotaxin (ATX) is a secreted phosphodiester-
ase that hydrolyzes lysophosphatidylcholine into the lipid mediator lysophosphatidic acid 
(LPA) (3). ATX was originally identified as an autocrine motility factor for human melanoma 
cells (4) and later found to be identical to plasma lysophospholipase D, the main enzyme 
accounting for LPA production in the circulation (5;6)
ATX is essential for embryonic development (7;8) and, when overexpressed in mice, it is an 
effector of tumor formation, angiogenesis and metastasis (reviewed in (9)). Of particular 
interest, transgenic expression of ATX or individual LPA receptors (LPA1-3) in mouse 
mammary glands induces late-onset, invasive mammary cancer (10). Furthermore, injec-
tion of ATX-expressing mammary carcinoma cells into nude mice enhances the formation of 
osteolytic bone metastasis (11).
In human malignancies, high ATX expression has been implicated in development and pro-
gression of prostate cancer (12), early-stage colorectal cancer (13) and Hodgkin lymphoma 
Figure 1. ATX expression in primary breast tumors. Tissue microarrays of primary breast tumors were ana-
lyzed for cytoplasmic ATX expression by IHC, using anti-ATX monoclonal antibody 4F1. (A) Representative 
tumors with high ATX expression levels. (B) Distribution of IHC scores in 193 breast tumors. (C) Pie chart 






















(14). Thus far, ATX expression patterns in breast cancer patients have not been adequately 
analyzed. In the present study, we examined ATX expression by immunohistochemical (IHC) 
analysis on tissue microarrays derived of 193 mammary carcinomas, and explored possible 
correlations with clinico-pathological and prognostic characteristics.
RESULTS
We analyzed ATX protein expression in a series of primary tumors by IHC on tissue micro-
array sections using anti-ATX monoclonal antibody 4F1 (16). Specificity and reactivity of the 
4F1 antibody in tissue sections has been assessed previously (12;17). ATX IHC staining was 
observed specifically in carcinoma cells, with little or no ATX expression detectable in the 
surrounding stroma (Fig. 1A). Positive staining was found in the majority of tumors, with 
moderate to strong staining (scores 2 and 3) in 86% of all cases, while only very few tumors 
were ATX negative (Fig. 1B and Fig. 1C). Thus, ATX expression is a common feature of prima-
ry breast cancer, suggesting that ATX-LPA receptor signaling might play a role in mammary 
tumorigenesis and progression. 
Using the known gene expression data of this patient cohort (15), we analyzed the cor-
relation between ATX mRNA and protein expression. Unexpectedly, the IHC scores did 
not correlate with the mRNA expression pattern (p=0.28). Whereas the ATX IHC profile 
showed clear differences among patients, the mRNA expression pattern did not show much 
variability (Fig. 2). It should be noted that ATX mRNA expression levels represent the sum 
of intracellular and secreted ATX, while IHC analysis only detects the intracellular pool 
representing newly synthesized ATX. It is currently not clear how intracellular ATX levels 
relate to the secreted, LPA-generating, ATX pool. It seems likely that intracellular and ex-
tracellular levels are closely correlated. However, future analysis is needed to test this 
hypothesis.
Figure 2. Correlation between ATX mRNA and protein expression. Boxplot showing the ATX mRNA expression per 
group of ATX IHC score (n=193). There is no clear correlation between ATX mRNA and protein expression 
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Next, we examined the association of ATX immunoreactivity with patient and tumor 
characteristics, including age, tumor size, differentiation grade as well as lymph node, Her2 
and progesterone receptor status. Breast cancer is a heterogeneous disease with different 
histological and molecular subtypes (18). Due to the known distinct behavior of ER positive 
breast cancer versus ER negative breast cancer, we analyzed these subgroups separately. As 
summarized in Table 1, no association between ATX expression and clinico-pathological pa-
rameters could be demonstrated. In addition, Kaplan-Meier analyses showed no significant 
correlation between ATX IHC score and patient survival (Fig. 3A). The ER-negative patient 
group showed a trend towards better survival, although this difference was not statistically 
ER positive ER negative
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Table 1. Association of ATX protein expression with clinico-pathological variables in primary breast tumors. The 
number of patients is indicated, with the column percentage between brackets. The p-values were calcu-
lated with the use of Chi square test, unless indicated otherwise. ATX low is defined as ATX IHC score 0-2; 
ATX high is defined as ATX IHC score 3; Her2: Her2 receptor (expression determined by IHC); PR: proges-
terone receptor (expression determined by microarray analysis); chemo- and hormonal therapy: adjuvant 
therapy. $ Fisher exact test; # Chi square test for trend; n=193.
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significant (univariate Cox regression for ER-positive group: hazard ratio (HR) 0.79, p=0.39, 
and for ER-negative group: HR 1.6, p=0.25; multivariate Cox regression for ER-positive group: 
HR 0.78, p=0.38, and for ER-negative group: HR 1.6, p=0.29). Similar as for the IHC scores, 
ATX mRNA expression profiles also failed to show a correlation with patient outcome (Fig. 
3B). In line with our results, a recent study reported absence of a correlation between ATX 
mRNA levels and classical prognostic parameters in breast cancer patients (11). Thus, we 
conclude that ATX expression profiles are not significantly correlated with clinical outcome 
in human primary breast cancer.
Figure 3. ATX expression and metastasis-free survival in human breast cancer. Kaplan-Meier survival analyses of 
patient survival, defined as time to any metastatic event, versus (A) ATX IHC score in two groups: ATX low 
is defined as ATX IHC score 0-2, ATX high is defined as ATX IHC score 3; and (B) ATX mRNA expression in two 
groups: ATX low versus ATX high. For panels A and B, patients were divided in ER positive (left graph) and 
ER negative (right graph) groups. There is no significant correlation between ATX expression and survival 
in either data set. Blue line: ATX low group, green line: ATX high group. Censored data are depicted with a 
vertical line. The p-values were calculated using the Log Rank Mantel-Cox test (n=193).
me to metastac event (years)





















me to metastac event (years)





















me to metastac event (years)




















me to metastac event (years)





















ATX IHC score: ER+ ATX IHC score: ER-
ATX mRNA score: ER+ ATX mRNA score: ER-
p: 0.39 p: 0.25
p: 0.45 p: 0.87
48
Autotaxin expression profiling in human breast cancer
FUTURE PROSPECTS
Mammary carcinoma cells are highly responsive to LPA, particularly with respect to cell 
migration (19), and a causal link between ATX-LPA receptor signaling and mammary cancer 
has been reported in a transgenic mouse model (10). This suggests that excessive ATX-LPA 
signaling is sufficient for tumor initiation and progression in mice. We thus hypothesized 
that ATX would play a role in human breast cancer, and might serve as a prognostic factor. 
However, the results of our tissue microarray analysis show that ATX expression in breast 
cancer does not correlate with clinical and prognostic characteristics. Of note, high ATX 
expression does not necessarily imply enhanced LPA signaling, as the interplay between 
substrate availability, product degradation and the LPA receptor expression profile together 
will determine the outcome of ATX action. A previous study showed that LPA2 expression is 
linked to invasive ductal breast carcinoma (20). It will be interesting to examine how LPA re-
ceptor expression profiles, either by itself or in combination with ATX expression, correlate 
with clinical outcome in human breast cancer.
EXPERIMENTAL PROCEDURES
Patients 
This study was carried out using tumor samples from a breast cancer patient cohort of the 
fresh-frozen tissue bank of the Netherlands Cancer Institute (15). All patients were younger 
than 53 years and were diagnosed with stage I or II breast cancer, lymph node negative 
or positive, containing both estrogen receptor (ER) negative and ER positive tumors. The 
median duration of follow-up (defined as time to any metastatic event) among all patients 
was 9.9 years, with 12.1 years for the patients without a metastasis event and 2.9 years for 
the patients with a metastasis event. All patients had been treated by breast conserving or 
ablative therapy followed by radiotherapy and/or adjuvant chemotherapy and/or hormo-
nal therapy. The study was approved by the medical ethics committee of the Netherlands 
Cancer Institute.
Immunohistochemistry 
Blocks of formalin-fixed, paraffin-embedded primary breast cancer tissue were prepared 
using a tissue arrayer. For immunohistochemistry, sections were heated at 75°C for 30 min., 
deparrafinized in xylene and rehydrated via a series of graded alcohols. After washing with 
TBS (J.T. Baker BV) for 5 min., sections were boiled for 15 min. in citrate buffer pH 6 (trina-
trium-citrate-dihydrate 8.2 mM, citric acid 0.18 mM) for antigen retrieval and cooled down 
for 1 hour. Sections were then incubated with peroxidase blocking solution (Immunovision 
Technologies) for 10 min., washed with TBS for 5 min. and incubated overnight with rat 
monoclonal antibody 4F1 raised against a human ATX polypeptide (amino acid 58-182) (16), 
1:50 dilution at 4°C. Next, sections were washed for 5 min. with TBS, incubated with post-
antibody blocking/polymer penetration enhancer solution (Immunovision Technologies) for 
15 min., washed, incubated with polymerized HRP-anti-mouse/rabbit IgG (Immunovision 
Technologies), washed, and incubated with DAB and hematoxyline. ATX staining in the tu-
mor sections was scored by a consultant breast pathologist (JW) as 0, 1, 2, 3 corresponding 
respectively to negative, faint, moderate, strong staining intensity. The highest score out 
of three cores from the same tumor was used for analysis. If one or two cores out of three 
failed, the highest value of the remaining core(s) was included. Only the tumor component 
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was considered when judging staining and sections containing stromal tissue without carci-
noma cells were discarded from the analysis. This resulted in a total number of 193 patient 
samples that were scored for ATX expression.
Statistical analysis 
Time to metastasis for two ATX groups (IHC score 0-2 versus 3) was estimated according 
to the Kaplan-Meier method. In addition, we tested for trend, using the significance of the 
coefficient for the continuous ATX IHC score 0-3. The association between ATX IHC score (4 
groups: score 0, 1, 2 and 3) and ATX mRNA expression was tested using the Kruskall Wallis 
test. Associations between ATX IHC score and clinico-pathological variables were evaluated 
by a Chi square test, unless otherwise indicated. 
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ABSTRACT
Autotaxin (ATX), or ecto-nucleotide pyrophosphatase/
phosphodiesterase 2 (ENPP2), is a secreted lysophospho-
lipase D that hydrolyzes lysophosphatidylcholine into the 
lipid mediator lysophosphatidic acid (LPA), a mitogen and 
chemoattractant for many cell types. ATX has been impli-
cated in tumor progression and inflammation, and might 
serve as a biomarker. Here we describe the development 
of a fluorescent activity-based probe that covalently binds 
to the active site of ATX. The probe consists of a lysophos-
pholipid-based backbone linked to a trapping moiety that 
becomes reactive after phosphate ester hydrolysis, and a 
Cy5 fluorescent dye to allow visualization of active ATX. 
The probe reacts specifically with the three known iso-
forms of ATX, it competes with small-molecule inhibitors 
for binding to ATX, and allows ATX activity in plasma to be 
determined. Our activity-based reporter will be useful for 
monitoring ATX activity in biological fluids and for inhibi-
tor screening. 
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INTRODUCTION
Autotaxin (ATX), also known as ENPP2 (ecto-nucleotide pyrophosphatase/phosphodi- 
esterase 2), is a secreted glycoprotein (~120 kDa) that functions as a lysophospholipase D to 
hydrolyze lysophosphatidylcholine (LPC) into the lipid mediator lysophosphatidic acid (LPA) 
(1;2). LPA acts on specific G protein-coupled receptors and thereby evokes a great variety 
of cellular responses, including cell proliferation, migration and survival (3). ATX is a multi-
domain protein and uses a single catalytic site at residue T210, which harbors the active-site 
nucleophile (Fig. 1) (4).
ATX was originally identified as an autocrine motility factor for melanoma cells (5) and was 
later found to enhance experimental metastasis of Ras-transformed NIH3T3 cells (6). Since 
then, many studies have shown a role for ATX-LPA signaling in tumor progression (7-9), and 
gene knockout studies have uncovered a vital role for ATX in vascular development (10;11). 
ATX is expressed and secreted by diverse tissues and is present in the circulation; virtually 
every cell type expresses functional LPA receptors. The ATX-LPA receptor axis has been im-
plicated not only in tumor progression but also in chronic inflammation (12), fibrotic disease 
(13) and neurological disorders (14;15), making it an attractive target for therapy. We and 
others have developed potent small-molecule inhibitors of ATX that lower circulating LPA 
































Figure 1: The ATX-LPA receptor signaling axis. Secreted ATX converts LPC to LPA in the extracellular environ-
ment. LPA binds to specific G protein-coupled receptors leading to the activation of downstream signaling 
cascades that trigger cell migration, proliferation and survival.
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Several studies indicate that secreted ATX might serve as a biomarker. In particular, serum 
ATX levels are significantly elevated in patients with follicular lymphoma (FL) and corre-
late with tumor burden (19). Furthermore, ATX/lysoPLD activity is enhanced in serum from 
patients with chronic liver disease (20) and in malignant effusions from ovarian cancer 
patients (9). Therefore it will be useful to develop activity-based probes (ABPs) to monitor ATX 
activity in body fluids. ABPs are reagents that contain key recognition and reporter elements 
that allow the study of target enzymes based on catalytic activity instead of expression 
levels (21). ABPs have proved useful for monitoring enzyme function in complex biological 
systems, for the discovery of biomarkers, and for inhibitor profiling (21;22). 
Here, we report the design, synthesis and characterization of a fluorescent ABP for ATX. By 
using recombinant ATX and inhibitor competition experiments, we validate the ability of 
this reagent to label the ATX active site. In particular, our ABP can label ATX activity in serum 




The ATX activity-based probe (ATX-ABP) consists of four major components: a recognition 
element, a trapping device, a linker, and a reporter group (Scheme 1A). The lysophospho-
lipid-based recognition element defines the specificity of the target protein. The latent trap-
ping device functions as a chemical tool for covalent binding upon activation and gene-
rates a reactive intermediate upon phosphate ester hydrolysis, thereby covalently reacting 
with ATX in an activity-dependent manner (Scheme 1B). This trapping device has previously 
been used to probe protein tyrosine phosphatase activity (23-27). Upon ATX-mediated clea-
vage of the phosphodiester bond in the probe, the released intermediate undergoes rapid 
1,6-elimination of the fluoride and generates a reactive quinone methide species that, in 
turn, traps nearby nucleophiles in the ATX active site; this results in covalent labeling of 
ATX in an activity-dependent manner. Incorporation of a fluorescent dye allows visualization 
of active ATX. Sulfoindocyanine Cy5 was chosen as a marker because of its good solubility 
in aqueous solutions and its compatibility with most fluorimetric equipment. The dye was 
connected to the trapping device through a hydrophilic (ethylenedioxy)diethylamine linker. 
Chemical synthesis
ATX-ABP was prepared via a convergent synthetic approach as shown in Scheme 2. In brief, 
4-hydroxymandelic acid was condensed with Boc-2,2’-(ethylenedioxy)diethylamine (1, EDC/
HOBt/DMF) to give compound 2 in 90% yield. The 2-O-methoxymethyl (MOM)-protected 
lipid building block 3 was prepared by using previously reported protocols with minor modi-
fications (Scheme 3) (27;28). The two building blocks were connected by phosphoramidite 
chemistry. Lipid building block 3 was treated with chloro(diisopropylamino)methoxy phos-
phine and subsequently building block 2 was added to the phosphine intermediate. After 
oxidation with tert-butyl hydroperoxide, the phosphodiester product 4 was obtained in a 
37% overall yield (three steps). The benzylic fluoride functionality was introduced by treat-
ing 4 with diethylaminosulfur trifluoride (DAST). The fluorinated product 5 was obtained in 
68% yield. Removal of MOM and methyl ester was achieved simultaneously with TMSBr and 
the crude product 6 was subsequently treated with TFA in dichloromethane to remove the 
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Boc group (7). Crude TFA salt 7 was coupled with Cy5-NHS ester to afford ATX-ABP in 8% 
yield after purification. 
Activity labeling of recombinant ATX
ATX-ABP was tested for its ability to label recombinant ATX in vitro. Increasing concentra-
tions of ATX-ABP (up to 100 μM) were incubated with purified recombinant ATX with or 
without bovine serum albumin (BSA). Proteins were separated by SDS-PAGE, and protein 
labeling was analyzed by in-gel fluorescence measurements. At 1 μM of ATX-ABP, a fluores-
Scheme 1: Chemical structure of the fluorescent activity-based probe for ATX (ATX-ABP) and the labeling reaction. 
(A) The fluorescent activity probe (ATX-ABP) has four structural components: a lysophospholipid-based 
backbone as a recognition element, a latent trapping device reactive unit (derived from p-hydroxymandelic 
acid), a linker and the sulfoindocyanine Cy5 dye as fluorescent tag. (B) Reaction mechanism of ATX labeling 
with ATX-ABP; only one of the potential products resulting from cross-linking is shown. Nuc: nucleophile.
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cent signal became apparent, and more intense labeling was measured at higher concentra-
tions of ATX-ABP (Fig. 2A). Increasing the incubation time (at a fixed probe concentration) 
also resulted in more labeling (Fig. 2B). Importantly, ATX-ABP did not label BSA, which is 
present at high concentrations in the circulation where it functions as a lipid carrier and 
scavenger of electrophiles. When probe was added to a mixture of BSA and ATX (Fig. 2C) or 
BSA alone (Fig. 2D) no significant BSA labeling was observed. Furthermore, ATX-ABP did not 
label alkaline phosphatase (AP; Fig. 2E), and the catalytically dead mutant ATX-T210A was 
resistant to reaction compared to active ATX (Fig. 3, lane 1). These results confirm that ATX-
ABP specifically labels ATX in an activity-dependent manner.  
Activity labeling of ATX isoforms
Alternative splicing of the ATX-encoding gene, ENPP2, results in three distinct isoforms. The 
best studied isoform, ATXβ (863 amino acids), is identical to plasma lysoPLD. The original 
“melanoma-derived” isoform, ATXα (915 amino acids) contains a 52 residue polybasic insert 
of unknown function in the catalytic domain. A “brain-specific” isoform (ATXγ) contains a 
short insert in the C-terminal domain. All three isoforms exhibit the same catalytic activity 
in vitro (29). The recombinant ATX isoforms were incubated for 1 hour at 37°C with 50 μM 
of ATX-ABP (Fig. 3, lanes 2-4). As expected, all three ATX isoforms reacted with the probe. 
Labeling was equally efficient for ATXβ and ATXγ. The ATXα isoform however labeled less 
efficiently, which might be explained by the known proteolytic cleavage of ATXα in its poly-
basic insert (29). Indeed, we could detect a major band that corresponds to the N-terminal 
cleavage fragment of ATXα, which did show some labeling. We conclude that ATX-ABP labels 




















































Scheme 2: Synthetic scheme of the fluorescent activity-based probe (ATX-ABP).
(a) 4-hydroxymandelic acid, HOBt, EDC, DMF, RT, overnight (90% yield); (b) Chloro(diisopropylamino)me-
thoxy phosphine, iPr2EtN, CH2Cl2, argon atmosphere, RT, 1 h; (c) 2, 0.45 M 1H-tetrazole in MeCN, CH2Cl2, 
RT, 4 h; (d), tert-butyl hydroperoxide (70 wt% in H2O), CH2Cl2, -70°C to RT, 4 h (37% yield, three steps);  (e) 
DAST, CH2Cl2, -70°C to RT, 2 h (68% yield);  (f) TMSBr (10 equiv.), CH2Cl2, 0°C, 4 h, 0°C to RT, 1 h;  (g), TFA/ 
CH2Cl2 (1:1, v/v), RT, 1 h; (h) Cy5-NHS ester dye, iPr2EtN, DMF, RT, overnight. Steps (f) and (g) were per-
formed without purification of the products. The final product (ATX-ABP) was purified by reversed-phase 
HPLC (8% yield).
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ATX inhibitor profiling
Next, we used ATX-ABP in competition experiments with LPA (the product of ATX-mediated 
LPC hydrolysis) and the ATX inhibitor HA130 (IC50 ~ 30 nM) (17), as shown in Fig. 4. Recom-
binant ATX was incubated with increasing concentrations of inhibitor for 1 hour at 37°C and 
subsequently with 50 μM of ATX-ABP for 15 minutes at 37°C. In-gel analysis showed that 
LPA did not compete with ATX-ABP, as demonstrated by unchanged fluorescence intensity of 
ATX incubated with increasing concentrations of LPA prior to labeling (Fig. 4A). In contrast, 
HA130 caused a dose-dependent loss of fluorescence intensity, reflecting a decrease in cat-
alytic activity (Fig. 4B). These experiments show that ATX-ABP is a useful tool for inhibitor 
profiling and suggest that the physiological product of ATX, namely LPA, does not interfere 
with ATX-mediated hydrolysis of our probe.   
Labeling of ATX activity in whole serum
We determined the ability of ATX-ABP to monitor ATX activity in whole serum and plasma 
ex vivo. Measurements of enzymatic activity and function in serum are challenging due to 
high levels of interfering albumin, a lipid carrier and electrophile scavenger present in con-
centrations between 30-40 mg/ml, whereas ATX levels in serum or plasma are relatively 
low (ca. 0.5 μg/ml) (30). Incubation of fetal calf serum with 2 μM ATX-ABP did not reveal 
a detectable fluorescent signal (data not shown). We therefore purified serum samples 
by anion-exchange column chromatography (eluted with a linear gradient of 0-1 M NaCl). 
Active fractions were identified using the FS3 ATX-activity assay (31) and incubated with 
2 μM ATX-ABP. Upon termination of the reaction, the samples were concentrated, and 
ATX activity was detected by SDS-PAGE. ATX labeling was observed in the active but not in 
the inactive fractions, although the observed labeling profile was weak (Fig. 5). Although a 
fluorescent signal could be detected, ATX levels were too low to be visualized by SYPRO or 
Coomassie Blue staining; this indicated the high sensitivity of our probe. To confirm speci-
ficity of the probe, labeled bands and controls were excised from the gel and analyzed by 
tandem mass spectrometry after trypsin digestion. Several tryptic ATX peptide fragments 
(CFELQEAGPPDCR, SYPEILTLK, GDCCTNYQVVCK and WWGGQPLWITATK) were found in the 
fluorescent bands but not in control lanes. These results show that ATX-ABP is able to label 



















Scheme 3: Synthesis of building block 3. Reagents: (a) PMBCl, NaH, DMF, RT, 1 h; (b) 5% (wt) p-TsOH, MeOH, 
rt, 1 h, directly used in the next step; (c) oleic acid, DMAP, DCC, CH2Cl2, RT, overnight; (d) MOMCl, DiPEA, 
DMF, RT, overnight; (e) DDQ, wet CH2Cl2, RT, overnight.
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Figure 2: Validation of ATX-ABP labeling.
(A) Labeling of recombinant ATX 
with increasing concentrations of 
ATX-ABP, showing a concentration-
dependent increase of the amount 
of labeling. (B) Time range label-
ing of recombinant ATX, incubated 
with 50 μM ATX-ABP for different 
time points. (C) Labeling of ATX 
and BSA in equal amounts with in- 
creasing concentrations of ATX-
ABP, indicating specific labeling of 
ATX. (D) Labeling of BSA for 1 hour 
at 37°C with increasing concentra-
tions of ATX-ABP. (E) Labeling of AP 
for 1 hour at 37°C with increasing 
concentrations of ATX-ABP.
Upper panels: in-gel fluorescence 
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Immunoprecipitation of labeled ATX from human plasma
In order to obtain a more efficient activity-based profiling procedure, we investigated a com-
bination of active-site labeling and immunoprecipitation. Plasma samples were incubated 
with 10 μM of ATX-ABP for 1 hour at 37°C and subsequently immunoprecipitated with anti-
ATX antibody 5E5 immobilized onto sepharose beads (30). ATX activity in human plasma was 
estimated by comparing the fluorescent signal of immunoprecipitated plasma ATX to that 
of recombinant ATX. Analysis of the fluorescence intensity indicated that the ATX activity 
in 1 ml of human plasma is equivalent to that of 0.5 μg recombinant ATX (Fig. 5), which is 
in agreement with the reported plasma ATX concentration of about 0.5 μg/ml (30). Thus, 
when combined with immunoprecipitation, ATX-ABP is a convenient tool to monitor ATX 
activity in plasma.
Figure 3: Labeling of recombinant ATX isoforms with ATX-ABP.
All three isoforms react with the probe, whereas the catalytically dead mutant ATX-T210A is resistant to 
reaction. Left panel: in-gel fluorescence scan, right panel: Coomassie blue staining. ATXβ: ATX teratocarci-


































































Figure 4: ATX inhibitor profiling.
(A) ATX-ABP labeling of recombinant ATX is not inhibited by LPA, in-gel fluorescence scan (B) ATX inhibitor 




We describe a convergent synthetic approach of an ATX active site-directed probe (ATX-
ABP) that efficiently labels recombinant ATX in a specific and activity-dependent manner. 
We have shown that ATX-ABP labels all three isoforms of ATX and that it can be used in 
inhibitor competition experiments. The inactive mutant ATX-T210A showed hardly any la-
beling, consistent with ATX-ABP labeling in an activity-dependent manner. 
Furthermore, we examined the labeling efficiency in more complex biological fluids. Recent 
studies have suggested that the serum ATX protein level is a promising marker for follicular 
lymphoma. The plasma ATX level in healthy individuals is about 0.5 μg/ml, whereas follicu-
lar lymphoma patients consistently show threefold higher ATX levels (19). Direct labeling of 
serum ATX with ATX-ABP proved difficult due to the high concentrations of serum albumin. 
Purification of serum ATX by anion exchange chromatography prior to labeling resulted in 
a weak signal, the specificity of which was confirmed by tandem mass spectrometry. To 
increase signal strength, we developed an affinity-purification protocol using ATX immuno-
precipitation after labeling. In this way ATX activity in human plasma was readily detectable. 
We showed that ATX-ABP did not cross-react with albumin in vitro, yet it remains challeng-
ing to measure enzyme activity in complex biological samples. ATX activity-based probes 
could provide new insights into ATX biochemistry, and could also serve as a diagnostic 
reagent and a tool for inhibitor profiling studies. 
In summary, we have synthesized and characterized a first-generation ATX-directed activity 
probe that labels active ATX specifically and efficiently. Affinity-purification after labeling 
enabled us to use ATX-ABP for activity profiling of biological fluids. Such probes may be 
useful to monitor ATX activity under normal and pathological conditions, and to profile ATX 


































Figure 5: Activity labeling of serum ATX. (A) Active pooled anion exchange fractions of fetal calf serum (lanes 
A-D) were incubated for 1 hour at 37°C with 2 μM ATX-ABP. Upper panel: in-gel fluorescence scan, lower 
panel: Coomassie Blue staining. (B) FS3 activity assay of the anion exchange fractions shown in panel A.
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CONCLUSIONS
We have developed a fluorescent activity-based probe that can detect and quantify ATX 
activity in human plasma. Upon cleavage of the phosphodiester bond, a highly reactive spe-
cies forms that cross-links nearby active-site residues. This approach allows the separation 
of labeled ATX prior to analysis and enables ATX activity readouts by SDS-PAGE followed by 
fluorescence scanning. This reagent is the first ATX activity reporter developed so far and it 
could, in principle, be developed into a diagnostic reagent to monitor ATX activity in body 
fluids. Moreover, ATX-ABP can be used in competition format with ATX inhibitors to guide 
their pharmacology, allowing ex vivo detection of ATX activity in body fluids after treatment 
with inhibitors.   
EXPERIMENTAL PROCEDURES
Chemical synthesis 
All reagents and starting materials were obtained from commercial suppliers at the highest 
grade available (Acros, Aldrich, and Merck) and used without further purification. 1H, 13C and 
31P NMR were recorded by using a Bruker ARX 400 spectrometer. 1H NMR spectra in CDCl3 
were referenced to residual CHCl3 at 7.24 ppm and 
13C NMR spectra to the central peak of 
CDCl3 at 77.0 ppm. 85% H3PO4 was used as external standard for 
31P NMR spectroscopy. ESI-
MS spectra were recorded on a LCT micromass/Waters mass spectrometer. Analytical TLC 
was performed with silica gel supported on aluminium sheets (silica gel, 60F254, 20x20 cm, 
Merck) and spots were visualized under UV light by staining with a solution of ammonium 
molybdate or a solution of ninhydrin, followed by charring at ~150°C. Column chromato-
graphy was performed with silica gel for chromatography Acros Organics (0.035-0.070 mm, 
60 Ǻ). 
Synthesis of the fluorescent probe 
Compounds 2 and 3 were synthesized by using modified published procedures (Scheme 2) 
(27;28).
0.25 0.50 21 A B DC
rec ATX (µg) human plasma FCS
Figure 6: Screening of ATX activity in human plasma.
Human plasma samples from healthy volunteers (1 ml) and FCS (1 ml) were first incubated with ATX-ABP 
and subsequently affinity-purified with an anti-ATX monoclonal antibody. Recombinant ATX, also labeled 
but not affinity-purified, is included as a standard. A, B: healthy female volunteers; C, D: healthy male 
volunteers.  Upper panel: in-gel fluorescence scan, lower panel: Western blot. The blot was incubated with 
an anti-ATX antibody (Cayman Chemical, Ann Arbor MI).
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Compound 2. A preactivated mixture of 4-hydroxylmandelic acid (893 mg, 4.8 mmol), EDC 
(922 mg, 4.8 mmol) and HOBt (648 mg, 4.8 mmol) was added to a solution of 1 (1 g, 4 mmol) 
in DMF (20 mL), and the reaction was stirred overnight at RT. The reaction mixture was 
evaporated to dryness. The product was purified by FCC (7% MeOH in CH2Cl2). Yield: 1.45 g 
(90%). Rf = 0.23 (10% MeOH in CH2Cl2); 
1H NMR (CDCl3, 400 MHz): δ = 7.12 (d, 2H; Ar), 6.63 
(d, 2H; Ar), 5.3 (s, 1H; benzylic CH), 5.16 (br s, 1H; OH), 4.94 (br s, 1H; OH) 3.55-3.25 (m, 10H; 
linker), 3.26 (m, 2H; linker), 1.42 ppm (s, 9H; Boc); 13C NMR (CDCl3, 101 MHz): δ = 173.59, 
157.12, 156.53, 130.82, 128.55, 115.99, 80.06, 74.19, 70.43, 70.27, 69.66, 40.54, 39.31, 
28.58 ppm; MS (ESI): m/z: 399.20 [M+H]+, m/z: 421.09 [M+Na]+, m/z: 365.07 [M-tBu+Na]+, 
m/z: 321.09 [M-Boc+Na]+, m/z: 437.15 [M+K]+.
Compound 3. 3-(4-methoxybenzyl)-sn-glycerol (III). To a solution of 1,2-O-isopropylidene-
sn-glycerol I (2.12 g, 16.06 mmol) in 100 mL of dry DMF was added NaH (1.09 g, 60%, 19.27 
mmol), followed by addition of p-methoxybenzyl chloride (2.6 ml, 19.27 mmol). The mix-
ture was stirred at RT for 2 h (TLC, II Rf = 0.71, 33% ethyl acetate/hexane). Excess NaH was 
destroyed by dropwise addition of MeOH. Solvent was evaporated and CH2Cl2 was added to 
extract. The CH2Cl2 layer was washed with brine and dried over MgSO4. After concentration, 
an oil was obtained and redissolved in 40 mL of MeOH containing p-toluenesulfonic acid 
monohydrate (153 mg, 0.05 equiv, 0.8 mmol). The mixture was stirred at RT for 2 h (TLC, III 
Rf = 0.25, 75% ethyl acetate/hexane). Next, NaHCO3 (100 mg) was added, and the solvent 
was evaporated. The residue was purified by flash chromatography on silica gel with 80% 
ethyl acetate in n-hexane to give 2.986 g of 3-(4-methoxybenzyl)-sn-glycerol (III) (83% yield 
from I): 1H-NMR (CDCl3, 400 MHz) d: 7.16 (d, 2H, phenyl), 6.79 (d, 2H, phenyl), 4.38 (s, 2H, 
PMBCH2O), 3.79-2.79 (m, 5H, CH2 and CH glycerol), 3.72 (s, 3H, MeO) ppm. 13C-NMR (CDCl3, 
101 MHz) d: 129.67, 129.41, 113.79, 73.11, 71.31, 70.68, 63.94, 55.20 ppm. MS (ESI): m/z 
= 235.40 [M+Na]+.
1-O-Oleoyl-3-(4-methoxybenzyl)-sn-glycerol (IV). To a solution of 3-(4-Methoxybenzyl)-sn-
glycerol III (2.93 g, 13.81 mmol) and oleic acid (4.68 mL, 16.57 mmol) in dry CH2Cl2 (100 mL) 
was added a solution of DCC (3.42 g, 16.57 mmol) and DMAP (844 mg, 6.91 mmol) in dry 
CH2Cl2 (50 mL). The solution was stirred for 16 h at RT, filtered, and concentrated in vacuo, 
and the residue was purified by flash chromatography on silica gel with 40% ethyl acetate 
in n-hexane to afford 4.45 g of IV (67%) as a colorless oil: Rf = 0.32 (ethyl acetate/hexane, 
1/20, v/v); 1H-NMR (CDCl3, 400 MHz) d: 7.18 (d, 2H, phenyl), 6.82 (d, 2H, phenyl), 5.23 (m, 
2H, CH= oleoyl), 4.95 (m, 1H, CH glycerol), 4.42 (s, 2H, PMBCH2O), 4.12-3.37 (m, 4H, CH2 
glycerol), 3.74 (s, 3H, MeO), 2.24 (m, 2H, CH2CO oleoyl), 1.93 (m, 4H, CH2CH= oleoyl), 1.54 
(m, 2H, CH2CH2CO oleoyl), 1.18 (m, 20H, CH2 oleoyl), 0.82 (m, 3H, CH3 oleoyl) ppm. 13C-NMR 
(CDCl3, 101 MHz) d: 173.90, 159.34, 130.20, 129.98, 129.70, 129.40, 113.77, 73.15, 70.53, 
68.71, 65.35, 55.25, 34.12, 31.88, 29.75, 29.68, 29.63, 29.50, 29.30, 29.14, 29.08, 27.20, 
27.15, 24.88, 22.62, 14.10 ppm. MS (ESI): m/z = 499.71 [M+Na]+.
1-O-Oleoyl-2-O-methoxymethyl-3-(4-methoxybenzyl)-sn-glycerol (V). Chloromethyl methyl 
ether (0.75 mL, 10 mmol) was added to a stirred solution of IV (498 mg, 1 mmol) and DiPEA 
(1.74 mL, 10 mmol) in dry CH2Cl2 (50 mL) under N2 at 0 °C. The mixture was stirred at 0 °C 
for 2 h and overnight at RT. The organic layer was washed with water, brine and then dried. 
Product V (496 mg, 95% yield) was obtained after removal of the solvent and purification 
by chromatography (hexane/EtOAc 4/1). Rf = 0.61 (8/2 Hex/EtOAc). 1H-NMR (CDCl3, 400 
MHz) d: 7.23 (d, 2H, phenyl), 6.87 (d, 2H, phenyl), 5.33 (m, 2H, CH= oleoyl), 4.71 (m, 2H, CH2 
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MOM), 4.45 (s, 2H, PMBCH2O), 4.24-3.96 (m, 3H, CH and CH2 glycerol), 3.80 (s, 3H, MeO), 
3.53 (m, 2H, CH2 glycerol), 3.40 (s, 3H, MeO MOM), 2.30 (m, 2H, CH2CO oleoyl), 1.98 (m, 4H, 
CH2CH= oleoyl), 1.58 (m, 2H, CH2CH2CO oleoyl), 1.25 (m, 20H, CH2 oleoyl), 0.86 (m, 3H, CH3 
oleoyl) ppm. 13C-NMR (CDCl3, 101 MHz) d: 173.79, 159.44, 130.43, 130.21, 129.94, 129.48, 
128.26, 128.10, 113.98, 96.24, 74.02, 73.29, 70.53, 69.55, 64.24, 55.70, 55.47, 34.40, 31.88, 
29.74, 29.39, 27.38, 27.10, 14.33 ppm. MS (ESI): m/z = 542.65 [M+Na]+.
1-O-Oleoyl-2-O-methoxymethyl-sn-glycerol (3). DDQ (258.8 mg, 1.14 mmol) was added to a 
solution of V (298.2 mg, 0.57 mmol) in CH2Cl2 (40 mL) and H2O (0.4 mL) and the reaction was 
stirred overnight at RT. The reaction mixture was diluted with CH2Cl2, washed with saturated 
NaHCO3, water, and then brine, dried (MgSO4), and evaporated. The product was purified 
by FCC (40% EtOAc in n-Hexane). Yield: 193.2 mg (84%). Rf = 0.41 (40% EtOAc in n-Hexan). 
1H-NMR (CDCl3, 400 MHz) d: 5.34 (m, 2H, CH= oleoyl), 4.74 (s, 2H, CH2 MOM), 4.20-3. 60 
(m, 5H, CH and CH2 glycerol), 3.43 (s, 3H, MeO MOM), 2.31 (m, 2H, CH2CO oleoyl), 2.01 (m, 
4H, CH2CH= oleoyl), 1.60 (m, 2H, CH2CH2CO oleoyl), 1.25 (m, 20H, CH2 oleoyl), 0.85 (m, 3H, 
CH3 oleoyl) ppm. 13C-NMR (CDCl3, 101 MHz) d: 173.95, 130.22, 129.92, 96.85, 77.94, 62.83, 
62.61, 55.95, 34.36, 29.53, 29.33, 27.42, 25.10, 14.32 ppm. MS (ESI): m/z = 422.87 [M+Na]+.
Compound 4. 1-O-Oleoyl-2-O-methoxymethyl-sn-glycerol 3 (40.1 mg, 0.1 mmol) was 
co-evaporated with MeCN (3x) and dissolved in anhyd. CH2Cl2 (5 mL) under an argon 
atmosphere. iPr2EtN (0.02 ml, 0.11 mmol) and chloro(diisopropylamino)methoxyphosphine 
(0.02 ml, 0.11 mmol) were added to this solution, and the reaction was stirred for 1 h at RT. 
1H-Tetrazole (0.5 ml, 0.2 mmol of a 0.45 M stock solution in MeCN) was added to this stirring 
solution. Meanwhile compound 2 (39.8 mg, 0.1 mmol) was co-evaporated with MeCN (3x), 
diluted in anhyd. CH2Cl2 (10 ml) and added to the reaction mixture. The solution was stirred 
overnight at RT and cooled to −70°C, while tert-butyl hydroperoxide (0.02 ml, 0.13 mmol 
of 70 wt % in H2O) was added dropwise. After stirring the reaction at −70°C for 10 min, the 
reaction was allowed to come to RT over 2 h, diluted with CH2Cl2 (10 mL) and washed with 
a sat. Na2SO3 solution (20 mL). The organic layer was extracted with H2O (2×20 mL), brine 
(20 mL), then dried over anhyd. Na2SO4, filtered, and concentrated under vacuum to yield a 
colorless syrup. The residue was purified on a silica gel column (3% MeOH in CH2Cl2). Yield: 
32.6 mg (37% over three steps). Rf = 0.35 (5% MeOH in CH2Cl2); 
1H NMR (CDCl3, 400 MHz): 
δ = 7.69 (br s, 1 H; NH), 7.44 (d, 2H; Ar), 7.19 (d, 2H; Ar), 7.10 (br s, 1 H; NH), 5.34 (m, 2H; 
CH= oleoyl), 5.15-5.00 (br s, 1H; benzylic CHOH), 4.69 (s, 2H; CH2MOM), 4.30-3.95 (m, 5H; 
CH, CH2 glycerol),  3.87 (s, 3H; CH3OP isomer 1), 3.84 (s, 3H; CH3OP isomer 2), 3.68-3.48 (m, 
10H; linker), 3.37 (s, 3H; CH3O MOM), 3.34-3.24 (m, 2H; linker), 2.32 (m, 2H, CH2CO oleoyl), 
2.01 (m, 4H, CH2CH= oleoyl), 1.61 (m, 2H; CH2CH2CO oleoyl), 1.42 (s, 9H; Boc), 1.28 (m, 20H; 
CH2 oleoyl), 0.88 ppm (m, 3H; CH3 oleoyl). 
13C NMR (CDCl3, 101 MHz): δ = 173.43, 129.97, 
129.67, 128.26, 119.99, 96.10, 96.06, 73.30, 73.22, 73.16, 70.29, 70.23, 70.20, 70.12, 69.50, 
67.17, 67.11, 62.77, 62.75, 55.63, 40.42, 40.37, 39.04, 34.03, 31.86, 29.72, 29.66, 29.61, 
29.57, 29.48, 29.43, 29.28, 29.22, 29.14, 29.07, 29.06, 28.34, 27.18, 27.13, 24.80, 22.64 
ppm; 31P NMR (CDCl3 162 MHz): δ = -5.282 ppm. MS (ESI): m/z: 897.14 [M+Na]
+, m/z: 841.16 
[M-tBu+Na]+, m/z: 797.20 [M-Boc+Na]+.
ATX-ABP. Dimethylaminosulfur trifluoride (0.01 ml, 0.08 mmol) was added to a solution of 
4 (15 mg, 0.02 mmol) in CH2Cl2 (5 mL) under argon at -78°C, and the reaction mixture was 
stirred for 3 h. When TLC monitoring (2% methanol in CH2Cl2) showed complete consump-
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tion of 4, CH2Cl2 was added to the reaction, and the organic layer was washed with a sat. 
solution of NaHCO3 (3x) and brine. The organic extracts were dried over MgSO4, filtered, 
and evaporated. The remaining colorless solid was purified by column chromatography over 
silica gel (2% MeOH in CH2Cl2) to afford 5 as colorless oil (10.3 mg, yield 68%). Compound 
5 (30 mg, 34.21 μmol) was co-evaporated with MeCN (3x), diluted in anhyd. CH2Cl2 (2 mL) 
and placed under an argon atmosphere. The solution was cooled to 0°C and trimethylsilyl 
bromide (0.04 ml, 0.342 mmol) was added under argon, and the reaction mixture was first 
stirred for 4 h at 0°C and then for 1 h at RT. The reaction mixture was poured into a sat. solu-
tion of NaHCO3, acidified and then extracted with CH2Cl2 (3x) and washed with brine. The 
organic extracts were dried over MgSO4, filtered, and evaporated. Product 6 was directly 
used for the following reaction without further purification. MS (ESI): m/z: 836.71 [M+18]+. 
Crude product 6 was dissolved in TFA/CH2Cl2 (1:1, v/v, 2 ml). After 1 h the reaction mixture 
was evaporated, and the remaining amorphous TFA salt was dissolved in a minimal amount 
of H2O/MeCN and freeze-dried. MS (ESI): m/z: 741.55 [M+Na]
+. The resulting product 7 was 
directly used in the following reaction without further purification. To a solution of 7 in DMF 
(1 ml) was added iPr2EtN (6 μl, 34.21 μmol) and Cy5 NHS ester (26 mg, 34.21 µmol).  The 
reaction mixture was stirred overnight at RT and solvents were then removed under re-
duced pressure to give a blue film, which was purified by reversed-phase HPLC on a semi-
preparative Vydac C8 column by using a linear gradient (20-95% MeCN) to afford 4 mg of 
pure fluorescent ATX-ABP (8% after HPLC purification). 1H NMR (CDCl3, 400 MHz): δ = 7.70 
(br s, 1 H; NH), 7.48 (d, 2H; Ar), 7.23 (d, 2H; Ar), 6.90-6.83 (br s, 1 H; NH), 5.77 (d, J = 48.3 Hz, 
1H; benzylic CHF), 5.34 (m, 2H; CH= oleoyl), 5.18 (m, 1H; CH glycerol), 4.40-3.30 (m, 16H, CH2 
glycerol and linker), 2.34 (m, 2H; CH2CO oleoyl), 2.00 (m, 4H; CH2CH= oleoyl), 1.62 (m, 2H; 
CH2CH2CO oleoyl), 1.25 (m, 20H; CH2 oleoyl), 0.88 ppm (m, 3H; CH3 oleoyl); 
31P NMR (CDCl3 
162 MHz): δ = -5.656 ppm. MS (ESI): m/z 1434.55 [M+2K-H]+.
Activity profiling: covalent labeling with ATX-ABP
The indicated amount of purified recombinant ATX was incubated with ATX-ABP in reaction 
buffer (containing 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 50 mM Tris pH 7.8) at 
37°C for 1 h. A range of concentrations of ATX-ABP was prepared by dilution in reaction buf-
fer of a stock solution (10 mM) of probe in MeOH containing 10% DMSO. The reactions were 
quenched by the addition of an equal amount of reducing sample buffer followed by heating 
at 70°C for 10 min. Protein was separated by 4-12% SDS polyacrylamide gel electrophoresis 
(SDS-PAGE). The fluorescent signal was detected using a PerkinElmer scanner (625-680 nm). 
Proteins were then visualized by staining with Coomassie Blue or SYPRO.
ATX inhibitor profiling 
Purified recombinant ATX was incubated with LPA and ATX inhibitor HA130 in reaction buf-
fer (containing 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 50 mM Tris pH 7.8) at 
37°C for 1 h. A range of concentrations of the LPA and ATX inhibitor HA130 was obtained by 
dilution in reaction buffer from a stock solution (10 mM) in DMSO. Subsequently, samples 
were incubated with ATX-ABP (50 μM) at 37°C for 15 min as described above. 
ATX enrichment from fetal bovine serum 
Fetal bovine serum (FBS) was purified with anion-exchange chromatography (SP Sepharose 
TM Fast Flow). FBS was diluted with 50 mM TRIS buffer (pH8) and loaded onto the column. 
The column was eluted with a linear gradient of NaCl (0-1 M). Active fractions (100 mM 
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NaCl) were identified by using a commercially available FS3 ATX-activity assay (Echelon) (31). 
Active fractions were incubated with 2 μM probe for 1 h at 37°C as described above.
FS3 ATX-activity assay 
FS3 was obtained from Echelon Bioscience and maintained as a 1 mM stock solution in 
Tris-buffered saline. Purified fractions collected from the anion exchange chromatography 
were diluted with Tris-buffered saline (140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
50 mM Tris, pH 7.8) containing 0.2 μg/μl fatty acid free BSA (BSA-FAF) and 2.5 μM FS3 at 
a concentration of 100 μM and incubated in a dark flat-bottom 96-well plate overnight at 
37°C. The increase in fluorescence was measured in a Victor Wallac 96-well plate reader 
(485/535 nm). 
MS analysis and in-gel digestion of proteins 
Selected Coomassie-blue-stained gel bands were excised and digested with trypsin using a 
Proteineer DP digestion robot (Bruker, Bremen, Germany), by following the protocol sup-
plied by the manufacturer.  This protocol includes destaining, reduction and alkylation, fol-
lowed by overnight digestion with trypsin. After digestion tryptic fragments were extracted 
with 50:50:1 H20/MeCN/formic acid. Extracts were pooled and lyophilized.
Mass spectrometry and database searching 
Lyophilized preparations were dissolved in H20/MeCNl/formic acid (95:3:0.1, v/v/v) and sub-
sequently sequenced by tandem mass spectrometry. Peptides were analyzed by nanoflow 
liquid chromatography using an Agilent 1100 HPLC system (Agilent Technologies) coupled 
on line to a 7-tesla LTQ-FT mass spectrometer (Thermo Electron, Bremen, Germany). The 
chromatographic system consisted of the following components. ReproSil-Pur C18-AQ, 3 
µm (Dr. Maisch GmbH, Ammerbuch, Germany) was used as a resin for the analytical nano-
column and AQUA-C18 5 μm was used as a resin for the trapping column. Columns were 
prepared in house. The end of the nanocolumn was drawn to a tip (ID approximately 5 μm), 
from which the eluent was sprayed into the mass spectrometer. Peptides were trapped at 5 
µl/min on a 1 cm column (100 µm internal diameter, packed in house) and eluted to a 15 cm 
column (50 µm internal diameter, packed in house) at 150 nl/min in a 60 min gradient from 
0 to 50% MeCN (0.1% formic acid). The mass spectrometer was operated in data-dependent 
mode, automatically switching between MS and MS/MS acquisition. Full-scan MS spectra 
were acquired in the FT-ICR with a resolution of 25 000 at a target value of 5 000 000. The 
two most intense ions were then isolated for accurate mass measurements by a selected 
ion-monitoring scan in FT-ICR with a resolution of 50 000 at a target accumulation value of 
50 000. The selected ions were then fragmented in the linear ion trap by using collision-in-
duced dissociation at a target value of 10 000. In a post-analysis process, raw data were con-
verted to peak lists using Bioworks Browser software, version 3.1. For protein identification, 
MS/MS data were submitted to the Swiss Prot database (version 51.6; 257964 entries) using 
Mascot version 2.1 (Matrix Science) with the following settings: 2 ppm and 0.8 Da deviation 
for precursor and fragment masses, respectively, and trypsin was the enzyme specified. 
IP and antibody coupling to CNBr activated sepharose 4B 
For the purification of ATX from plasma samples using an immunoprecipitation (IP) strategy 
the samples were first incubated with the fluorescent probe at a final concentration of 10 
μM. After incubation at 37°C for 2 h the samples were immediately incubated with the 
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precipitating monoclonal 5E5 antibody in PBS/10% NaHCO3 (30) coupled to CNBr activated 
sepharose 4B beads for 5 h tumbling at 4°C. Proteins were eluted by boiling for 10 min 
at 70°C in reducing loading buffer, separated by SDS-PAGE and scanned for fluorescence. 
Subsequently, proteins were transferred to nitrocellulose filters and probed with an anti-
ATX antibody (Cayman Chemical, Ann Arbor MI) and HRP-conjugated secondary antibody 
(Amersham).
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ABSTRACT
Autotaxin (ATX) is a secreted lysophospholipase D that 
converts lysophosphatidylcholine (LPC) into the lipid 
mediator lysophosphatidic acid (LPA), playing a key role 
in diverse physiological and pathophysiological processes. 
ATX exists in distinct isoforms, but isoform-specific func-
tions are still largely uncharacterized. The ATXα isoform, 
first identified as a motility factor for melanoma cells, dif-
fers from the canonical form ATXβ by having a 52-residue 
polybasic insert in the catalytic domain, containing a furin 
cleavage site and putative heparin-binding motifs. Here 
we report that secreted ATXα is cleaved by furin after resi-
due R340, yet remains structurally and functionally intact 
due to strong interactions within the catalytic domain. 
ATXα and ATXβ show similar catalytic efficiency towards 
LPC and are equally effective in stimulating cell migration. 
Through ELISA and surface plasmon resonance assays, we 
show that ATXα binds specifically and saturably to hepa-
rin with high affinity (Kd ~10
-8 M), whereas ATXβ does not. 
Furthermore, heparin enhanced the lysophospholipase D 
activity of ATXα up to two-fold, but did not affect ATXβ 
activity. These findings suggest that, owing to its basic 
insert, ATXα may preferentially bind to cell-surface hepa-
ran sulfate proteoglycans to promote localized LPA pro-
duction and signaling.
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INTRODUCTION
Autotaxin (ATX), or ecto-nucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), is a 
secreted lysophospholipase D (lysoPLD) that converts lysophosphatidylcholine (LPC) into the 
multifunctional lipid mediator lysophosphatidic acid (LPA). LPA signals through six distinct G 
protein-coupled receptors (1) and stimulates migration, proliferation and other functions in 
many cell types, both normal and malignant (2;3). However, anti-migratory effects of ATX-
LPA signaling have also been observed, depending on receptor expression profile and cell 
type (4). Studies in mice have uncovered key roles for ATX and LPA in a remarkable variety 
of physiological and pathophysiological processes, ranging from vascular development (5-7) 
and lymphocyte homing (8) to cancer (9;10), neuropathic pain (11) and pulmonary fibrosis 
(12), making the ATX-LPA signaling axis an attractive drug target.
Full-length ATX is synthesized as a pre-proenzyme. Upon removal of its N-terminal signal 
peptide followed by N-glycosylation, ATX is further processed by proprotein convertases 
and secreted via the classical secretory pathway as an active glycoprotein of 110-120 kDa 
(13;14). Mature ATX consists of two N-terminal somatomedin B-like (SMB) domains, a cen-
tral catalytic phosphodiester domain (PDE) and a C-terminal nuclease-like (NUC) domain. 
Recent structural studies show that ATX has evolved a deep lysophospholipid-binding 
pocket at the active site and a nearby open tunnel that could function as an LPA exit chan-
nel (15;16). The NUC domain serves to maintain the rigidity of the PDE domain, while the 
N-terminal SMB domains mediate binding of ATX to activated integrins (15;17). Integrin 
binding localizes ATX to the cell surface, providing a mechanism to generate and deliver LPA 
close to its cognate receptors (8;17-19). Whether ATX uses additional or alternative mecha-
nisms for spatially and temporally restricted LPA production is unknown. 
Alternative splicing gives rise to distinct ATX isoforms (20), yet isoform-specific functions 
of ATX are still largely uncharacterized. The canonical isoform, termed ATXβ, was originally 
cloned from teratocarcinoma cells (21) and later shown to be identical to plasma lysoPLD, 
accounting for LPA production in plasma and serum (22;23). Virtually all our current under-
standing of ATX is derived from studies on ATXβ. The original α-isoform was first isolated 
as an ‘autocrine motility factor’ from melanoma cells (24) and is characterized by a 52- 
residue polybasic insert of unknown function in the catalytic domain (3;25). Conceivably, the 
ATXα insert could confer different catalytic activity, (sub)cellular localization, processing or 
binding-partner preference. It was previously reported that the insert is subject to proteo-
lytic cleavage, leading to inactivation and degradation of ATXα (20); however, the latter no-
tion remains to be substantiated. 
In this study, we set out to examine the properties of ATXα relative to those of ATXβ, guided 
by the identification of a consensus furin cleavage site, putative heparin-binding motifs in 
the ATXα insert and by the crystal structure of ATXβ. Here we report two new findings. First, 
the ATXα insert is proteolytically cleaved by furin (or a furin-like endoprotease) at or near 
the cell surface, yet cleaved ATXα remains structurally and functionally intact. Second, the 
ATXα insert confers high-affinity binding to heparin and furthermore, heparin stimulates 
ATXα lysoPLD activity. On the basis of these findings, we suggest that ATXα may prefer-




Figure 1. ATX isoforms: domain architecture and structure. (A) The α, β and γ isoforms of ATX differ by the ab-
sence or presence of exon 12 or 21. All isoforms share the same domain architecture of two N-terminal 
somatomedin B-like domains (SMB-1 and SMB-2), a central phosphodiester domain (PDE) with the cata-
lytic residue T210, a C-terminal nuclease-like domain (NUC) and a ‘lasso loop’ connecting the PDE and NUC 
domains. ATXβ is the canonical isoform. ATXα contains a 52-residue insertion (amino acids 325-376) in the 
catalytic domain containing a proteolytic site at R340 (see Fig. 1B). ATXγ contains a 25-residue insertion 
(amino acids 594-618), encoded by exon 21, in the NUC domain. Transcript ID: ENST00000259486 (ATXα), 
ENST00000075322 (ATXβ), ENST00000522826 (ATXγ). (B) Amino acid sequence of the ATXα insert. Basic 
residues are indicated in blue. A consensus furin cleavage site (R-x-K/R-R) is located between residues 
R340 and K341 (arrow). (C) The crystal structure of rat ATXβ (ref. (15)), with the ATXα-specific insert shown 
as a flexible loop protruding out of the PDE domain. Domain colors are the same as in Fig. 1A, with LPA 
(blue-green), the phosphate (orange), the zinc ions (yellow spheres) bound to the active site, and the EF 
hand-bound calcium ion (blue sphere) shown in stick-and-sphere representation. The figure was prepared 
using Pymol (www.pymol.org).
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The long isoform of autotaxin (ATXα) undergoes intradomain cleavage
RESULTS AND DISCUSSION
ATXα: structure and expression
The human and murine ATX gene is organized in 27 exons. The best known splice variants, 
termed α, β and γ, differ by the presence or absence of sequences encoded by exons 12 
and 21 (Fig. 1A). ATXα contains an exon 12-encoded region of 52 residues in the catalytic 
domain. The canonical ATXβ isoform lacks exons 12 and 21, while the ‘brain-specific’ ATXγ 
isoform (formerly PD-1α) contains a 25-residue insert encoded by exon 21 in the NUC do-
main (26;27). A recently identified fourth isoform (ATXδ) has a four-residue deletion in the 
linker region (‘lasso loop’) between the PDE and NUC domain, but otherwise is identical to 
ATXβ (ref. (28) and AJH, unpublished results). 
Here we focus on the properties of ATXα relative to those of ATXβ. The ATXα insert is highly 
basic with a calculated pI ~11.5. Sequence inspection revealed a consensus cleavage site 
for the endoprotease furin (target sequence R-x-K/R-R; ref. (29)) between R340 and K341, 
as well as putative heparin-binding motifs which are commonly characterized by clusters 
of basic residues (Fig. 1B). The recently determined crystal structure of ATXβ allowed us 
to understand the localization of the insert in ATXα. The insert, which is predicted to be 
unstructured and solvent-exposed, starts right in front of an α-helix in the PDE domain. In 
Fig.1C, it is depicted as a flexible, hydrophilic loop that protrudes out of the PDE domain, 
relatively far away from the catalytic site and the lysophospholipid-binding pocket. Given its 
location and hydrophilic nature, the insert is unlikely to affect the tertiary structure of the 
ATXα catalytic domain. 
We examined ATX expression in various tissues and cell lines. In agreement with previous 
studies (8;10;20) and publicly available microarray data (30), highest ATX expression (all iso-
forms) was found in brain, kidney, spleen and lung, and somewhat lower expression in liver, 
skin and adipose tissue (Fig. 2A). Previous studies detected ATXα in kidney and liver (20) as 
well as in melanoma (24) and non-small-cell lung cancer cells (31). Using RT-PCR analysis, 
we detected ATXα in human skin fibroblasts (HF cells) and glioblastoma cells (SNB-78 and 
U-138). Analysis of mouse tissues shows  that ATXa expression is much less widespread than 
ATXβ (Fig. 2B). ATXα mRNA was detected in skin, presumably reflecting expression in dermal 
fibroblasts since skin-derived keratinocytes lacked detectable ATXα (data not shown). ATXα-
specific antibodies raised against sequences in the insert recognized overexpressed ATXα 
in HEK293 cells, but unfortunately could not detect endogenous ATXα  (LvM, unpublished 
results). It is of note that ATXα was consistently found co-expressed with ATXβ in the cell 
lines and tissues examined. We therefore examined whether both isoforms might inter-
act, but co-immunoprecipitation studies using HEK293 cells did not support this hypothesis 
(AJH, unpublished results). Using confocal microscopy, we found that ATXα and ATXβ show 
a very similar localization pattern in intracellular vesicles, consistent with both isoforms fol-
lowing the same vesicular trafficking route prior to secretion (Fig. 2C).    
Secreted ATXα undergoes furin processing at R340
Furin cleavage of ATXα at R340 is predicted to result in an N-terminal part of 340 amino 
acids and a C-terminal fragment of 575 amino acids. When expressed in HEK293 cells, 
secreted ATXα was consistently detected not only as a ~120 kDa band but also as two promi-
nent fragments of about 40 and 70 kDa, as shown by using antibodies against the N-terminal 
and C-terminal parts of ATX, respectively (Fig. 3A, lane 2). Three lines of evidence confirm 
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Figure 2. ATX isoform expression. (A) Quantitative PCR analysis of total ATX mRNA (all isoforms) relative to 
GAPDH in various mouse tissues. (B) RT-PCR analysis of ATXα and ATXβ expression in human cell lines 
and mouse tissues. Plasmid DNA analysis confirms specificity of the primers. Cell lines used: SNB78 and 
U138, glioblastoma; MDA-MB-435, melanoma; HF, foreskin fibroblasts. PCR primers were designed based 
on sequences around the ATXα-specific insert, resulting in an isoform-discriminative PCR. (C) Subcellular 















































































The long isoform of autotaxin (ATXα) undergoes intradomain cleavage
that ATXα is cleaved after R340 by furin or a furin-like endoprotease. First, mutant ATXα-
R340A was resistant to proteolysis (Fig. 3A, lane 3). Second, treatment of ATXα-expressing 
cells with decanoyl-Arg-Val-Lys-Arg-chloromethylketone (dec-RVKR-CMK), an inhibitor of 
furin-family endoproteases (32), prevented ATXα proteolysis (Fig. 3A, lanes 4-5). Third, 
addition of recombinant furin to HEK293-conditioned medium resulted in nearly complete 
cleavage of wild-type ATXα, but left ATXα-R340A intact (Fig. 3A, lanes 6-7). 
Importantly, the two ATXα fragments were detected only in the medium but not in cell 
lysates (Fig. 3A, lower panel), indicating that ATXα cleavage occurs at or near the cell surface 
rather than along the intracellular trafficking route. Indeed, although furin resides predomi-
nantly in the trans-Golgi network (TGN), furin (and related proteases) can also traffic to the 
cell surface and can be secreted to act in a paracrine manner (33;34). Thus, furin exerts a 
dual action on ATXα: first, it releases mature ATX from its precursor in the TGN and, second, 
it cleaves the ATXα insert at or near the cell surface.
Figure 3. Cleavage of the ATXα insert by furin. (A) Western blot analysis of conditioned media from HEK293 
cells expressing ATXβ (lane 1), ATXα (lanes 2, 4, 6) or mutant ATXα-R340A (lanes 3, 5, 7). Cleaved ATXα 
was detected in the medium (upper two panels), but not in cell lysates (lower panel). Cells were treated 
with 10 μM Dec-RVKR-CMK furin inhibitor overnight (lanes 4 and 5). Conditioned medium was treated 
with recombinant furin for 1 hour at 37�C (lanes 6 and 7). Anti bodies used: ATX C-term (polyclonal; Cay-
man) and ATX N-term (monoclonal; 4F1). The residual faint bands observed in lanes 3, 4, 5 and 7 may be 
attributable to ATXα cleavage at non-optimal cleavage sites present in the insert. (B) Detection of HEK293 
cell-conditioned media containing ATXα or ATXβ under reducing and non-reducing SDS-PAGE conditions. 
Note that ATXα cleavage is not observed under non-reducing conditions. Antibody: polyclonal anti-ATX 
C-term (Cayman). (C) The crystal structure of ATXβ with the ATXα insert superimposed. The N-terminal 
cleavage fragment is depicted in light grey, the C-terminal fragment in dark grey. The lysophopholipid 
binding pocket is composed by residues in both halves. LPA is depicted in the binding pocket. The disulfide 
bridge C157-C403 (arrow) connects the two fragments. The model was tilted 90°C on the x-axis compared 
to Fig. 1C to emphasize the extended interface between the two cleavage fragments. The polybasic insert 
of ATXα protrudes into the direction of the viewing plane, depicted by its first and last amino acid (325 and 
376, respectively). See text for further details about intramolecular interactions. 
B
IB: ATX  
C-term
ATXβ+ - - - - - -
ATXα- + - + - + -
ATXα(R340A)- - + - + - +
Rec. furin- - - - - + +
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Figure 4. LysoPLD activity of ATXα relative to ATXβ. (A) LysoPLD activity of ATXα (red) and ATXβ (blue) at 
increasing concentrations of LPC(18:1). (B) LysoPLD activity of ATXα before (red) and after (green) treat-
ment with recombinant furin. Data in (A) and (B) are expressed as means ± SD of three replicates and are 
representative of two independent experiments. (C) Chemotactic activity of ATXα and ATXβ, as measured 
by the transwell migration of A2058 melanoma cells using 2 nM recombinant ATX in the presence of 2 μM 











































V      ATXβ: 24 ± 0.5 nM/secmax
V      ATXα: 14 ± 0.5 nM/secmax
K    ATXβ: 158 ± 15 μMm













What could be the structural and functional consequences of the observed intrado-
main cleavage? When ATXα was examined under non-reducing conditions, there was no 
sign of proteolytic fragmentation indicating that ATXα remains intact (Fig. 3B). As can be 
inferred from the crystal structure (Fig. 3C), cleavage of ATXα at R340 leaves the N- and C- 
terminal parts tightly together due to an extended interaction surface area between both 
parts (10,980 Ǻ2, as calculated by PISA (35)). An analysis using FoldX (36) indicates that van 
der Waals interactions are primarily responsible for the stability of the interface (-76 kcal/
mol). Stability is further re-enforced by numerous hydrogen bonds (-69 kcal/mol), ionic 
interactions (-12 kcal/mol) and a disulfide linkage between Cys157 and Cys403 (-3 kcal/mol). 
Thus, the N- and C-terminal parts of ATXα normally form a very stable structure (calculated 
free energy of dissociation >100 kcal/mol) that can only be separated under reducing SDS-
PAGE conditions. This refutes the previously held notion that ATXα undergoes rapid proteo-
lytic fragmentation in vivo, being a new way of terminating catalytic activity (20).
ATX activity  
It was previously reported that ATXα and ATXβ show similar LPC substrate preferences, but 
enzyme kinetics were not examined (20). We measured lysoPLD activity of both isoforms by 
using LPC(18:1) as a substrate and monitoring the release of free choline. As shown in Fig. 
4A, we find that the catalytic efficiency (Vmax/Km) of ATXα towards LPC is about 70% of that 
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Figure 5.  Nucleotide phosphodiesterase activity of ATXα relative to ATXβ. (A) Phosphodiesterase activity of ATXα 
and ATXβ at increasing concentrations of pNP-TMP. (B) LPA-induced inhibition of ATX activity towards 1 
mM pNP-TMP. Based on the indicated IC50 values, the Ki values were calculated as 50 nM and 110 nM for 
ATXα and ATXβ, respectively. Data are expressed as means ± SD of three replicates and are representative 
of two independent experiments.























V      ATXβ: 347 ± 5 mM/secmax
V      ATXα: 65 ± 1 mM/secmax
K    ATXβ: 2.1 ± 0.1 mMm










IC    ATXα: 0.08 ± 0.01 μM50
IC    ATXβ: 0.16 ± 0.01 μM50
A B
Figure 6. ATX binding to immobilized heparin measured by ELISA. (A) ATXα and ATXβ were applied to heparin-
coated wells. Left panel: ATXα binds strongly to heparin, whereas ATXβ does not. Right panel: control 
experiments in which ATXα and ATXβ were directly immobilized to the wells (without heparin),  giving 
similar readings for both isoforms.  (B) Competition ELISA in which ATXα and ATXβ were pre-incubated 
with various amounts of heparin prior to application to heparin-coated wells. Binding of ATXα to immobi-
lized heparin was inhibited by pre-incubation with heparin in a dose-dependent manner.














































of ATXβ, primarily due to a lower Vmax value. Treatment of ATXα with recombinant furin (in 
order to ensure full cleavage of the insert) did not affect its lysoPLD activity (Fig. 4B). Fur-
thermore, ATXα and ATXβ were equally effective in stimulating the transwell migration of 
A2058 melanoma cells in the presence of LPC (Fig. 4C). 
In addition to lysophospholipids, nucleotides can also serve as substrates for ATX, although 
the in vivo relevance of the latter reaction is unclear. We found that the catalytic efficiency 
of ATXα towards pNP-TMP is >4-fold lower than that of ATXβ, mainly due to a lower Vmax (Fig. 
5A). We have currently no structural data that can explain this observation. 
The nucleotide phosphodiesterase activity of ATXβ is inhibited by LPA (37). As shown in Fig. 
5B, LPA(18:1) inhibited pNP-TMP hydrolysis by ATXα and ATXβ with Ki values of 50 nM and 




Figure 7. ATX binding to heparin measured by surface plasmon resonance. (A), (B). Surface plasmon reso-
nance analysis of ATX binding to heparin, showing sensorgrams of heparin binding to immobilized ATXα 
and ATXβ, respectively. Heparin concentrations are based on a MW of unfractionated heparin of 15 kDa. 
(C) Heparin saturation binding plot of ATXα (red) and ATXβ (blue). The inset shows the exponential, satu-
rable heparin-binding curve (red) and a linear component (blue; non-specific binding). The data were fit 
as described in the Experimental Procedures. Error bars correspond to the SD for a duplicate experiment. 
(D) Surface representation of ATXα indicating the electrostatic potential (-65 to +65 kT; positive charges 
in blue, negative charges in red). The polybasic insert of ATXα may cover a negative patch and might even 
















































































ATXα binds specifically to heparin
Given the presence of positively charged K/R clusters, we reasoned that the ATXα insert 
could confer high-affinity binding to heparin. Heparin is structurally very similar to hepa-
ran sulfate (HS), which is ubiquitously expressed as proteoglycans on cell surfaces and in 
extracellular matrices, where it recruits growth factors, chemokines and other molecules to 
fine-tune signaling events under both physiological and pathophysiological conditions (38-
40). Although heparin/HS-binding domains are characterized by clusters of basic residues, 
absolute consensus motifs cannot be defined from sequence data (41;42). High-affinity 
binding of ATX to heparin in vitro would point to a new mechanism for localized LPA produc-
tion and signaling in vivo. 
We first determined the binding of ATXα and ATXβ to unfractionated heparin using ELISA, 
in which recombinant ATX was added to heparin-coated wells. We found that ATXα binds 
strongly to immobilized heparin, whereas ATXβ hardly did (Fig. 6A). As a positive control, 
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Figure 8. Effect of heparin on ATX lysoPLD activity. LysoPLD activity of ATXα (red) and ATXβ (blue) using LPC 
(150 μM) as a substrate and increasing concentrations of heparin. Half-maximal effect was observed at 
~35 nM (based on a MW of heparin of 15 kDa). Data are expressed as means ± SD of three replicates and 


















   









both isoforms were immobilized directly to the wells (without prior heparin coating), which 
gave similar readings for both isoforms. We also used a competition ELISA, in which ATX was 
pre-incubated with various amounts of soluble heparin prior to addition to heparin-coated 
wells. In these experiments, we observed a dose-dependent inhibition of ATXα binding to 
immobilized heparin, confirming that the observed ATXα-heparin interaction is specific (Fig. 
6B). 
We next examined ATX-heparin binding using surface plasmon resonance, in which recom-
binant ATX was immobilized and heparin was used as the analyte (Fig. 7A-C). Again, we 
found that ATXα  binds heparin much stronger than does ATXβ. As can been seen in Fig. 
7A, heparin binds ATXα rapidly and dissociates slowly, consistent with specific binding. In 
contrast, ATXβ showed very fast heparin binding and dissociation kinetics (Fig. 7B), sugges-
tive of non-specific binding. Based on an average MW of heparin of 15 kDa, we determined 
the apparent Kd of ATXα for heparin to be approximately 10 nM. The Kd of ATXβ could not 
reliably be determined since heparin binding did not reach a plateau; however, it is at least 
10-fold lower than that of ATXα (Fig. 7C). We conclude that the basic insert of ATXα confers 
stable, high-affinity binding to heparin with a slow dissociation rate.
An electrostatic surface charge representation of ATX sheds some light on how and where 
heparin may bind (Fig. 7D). The model shows several positively charged patches, repre-
senting potential heparin/HS-binding regions common to both isoforms. It is seen that the 
basic insert of ATXα is located close to one of those patches in the catalyti c domain, sug-
gesting that the insert and the positively charged surface patch may act in a cooperative 
manner to enhance binding to heparin/HS. Co-crystallization studies using defined heparin/
HS fragments should help to test this scenario and, furthermore, uncover to what extent 
proteolytic cleavage at R340 may affect the heparin/HS interactions.
Interestingly, heparin enhanced the lysoPLD activity of ATXα towards LPC(18:1) up to two-
fold in a concentration-dependent manner (EC50 ~35 nM), whereas heparin had little or no 
effect on the activity of ATXβ (Fig. 8). This raises the possibility that interaction of ATXα with 
cell-associated HS proteoglycans may serve not only to generate and deliver LPA close to its 





We have shown that the polybasic insert of ATXα is susceptible to proteolytic cleavage by 
furin and confers high-affinity binding to heparin. It is noteworthy that ATXα cleavage occurs 
extracellularly, as it is not detectable in cell lysates, and leaves ATXα structure, stability and 
activity virtually unaltered. Although furin is the major proprotein convertase in the TGN, it 
is also found at the cell surface (34;43), where it can process secreted proteins such as, for 
example, the ADAMTS exo-enzymes (44). Thus there is precedent for cleavage of secreted 
proteins by cell surface-associated furin. Furthermore, soluble furin and the furin-like PACE4 
endoprotease can be secreted to act in a paracrine fashion over several cell diameters (33). 
In vivo, furin and PACE4 show distinct spatiotemporal distribution and delivery routes (33). 
Future studies should address whether secreted ATXα normally is processed by furin or 
PACE4, or whether both enzymes complement each other. The physiological consequences 
of ATXα cleavage are currently not clear, but it is tempting to speculate that proteolytic 
processing of secreted ATXα may serve to fine-tune its heparin/HS-binding properties in 
vivo, a scenario that warrants further investigation.
The finding that ATXα has nanomolar affinity for heparin strongly suggests that this isoform 
may preferentially localize to HS proteoglycans at the cell surface and/or in extracellular 
matrices. HS proteoglycans interact with numerous proteins, including growth factors and 
morphogens, and can facilitate the formation of growth factor gradients. Furthermore, our 
finding that heparin increases ATXα activity may point to a catalytic regulatory mechanism 
of this particular isoform. Previous studies have shown that ATXβ binds to activated integrins 
via its SMB domains, which provides one mechanism for localized production of LPA close 
to its cognate receptors (8;15;17;19). Binding of ATXα to heparin/HS proteoglycans may 
represent an additional, isoform-specifc mechanism for spatially and temporally restricted 
LPA production (18). It will be interesting to explore whether ATXα, HS and furin/PACE4 can 
be detected as a ternary complex at the cell surface or in extracellular  matrices. 
EXPERIMENTAL PROCEDURES
Cells and materials
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
fetal calf serum. The furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (Dec-
RVKR-CMK) was obtained from Biomol International, recombinant furin from New England 
Biolabs, LPC(18:1) and LPA(18:1) from Avanti Polar Lipids Inc. (Alabaster, AL), and heparin 
(from porcine intestinal mucosa; sodium salt ) from Sigma-Aldrich (cat. no. H4784). Anti-
bodies used: anti-Myc (9E10, home made); polyclonal anti-ATX against the C-terminal part 
of ATX (residues 573-588) (Cayman Chemical, Ann Arbor, USA); goat anti-ATX IgG  (R&D 
systems, Minneapolis, USA); monoclonal anti-ATX, 4F1, against an N-terminal polypeptide 
of ATX (residues 58-182) (ref. (45); kindly provided by J. Aoki). 
ATX constructs and recombinant protein
For ATX overexpression studies, human ATXβ was ligated in the pcDNA3 vector with a 3’ 
Myc tag as previously described (37). Human ATXα, ligated in pcDNA3 containing a 3’ Myc/
His tag was a generous gift from Dr. Andree Blaukat (Merck-Serono, Darmstadt, Germany). 
Mutant ATXα-R340A was generated using the Stratagene site-directed mutagenesis kit, with 
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the following primers: p686-forward (GGCTAAGAGACCTAAGGCGAAAGTTGCCCC) and p687-
reverse (GGGGCAACTTTCGCCTTAGGTCTCTTA GCC). For production of recombinant protein, 
ATXα and ATXβ were ligated in pcDNA5-FRT (Invitrogen) with a C-terminal Myc-tag and a 
6xHis-tag. HEK293 cells stably expressing ATXα or ATXβ were generated using the FLPin 
system (Invitrogen). Recombinant His-tagged ATX was purified from conditioned HEK293 
medium using POROS-20 MC columns pre-loaded with Ni2+, as previously described (46). 
The column was washed with eight to ten column volumes of buffer A (20 mM Tris-HCl pH 
8.0, 150 mM NaCl and 20 mM imidazole). ATX protein was eluted with a linear gradient of 
buffer A containing 750 mM imidazole.
Expression analysis
Cells were grown to confluency and total RNA was extracted using the RNeasy mini kit and 
column DNase treatment (Qiagen). First strand cDNA synthesis was performed using 2 μg 
total RNA, 0.5 μg oligo-dT primers (Promega), 500 nM dNTPs (Roche), 40 units RNAsin (Pro-
mega), 10 mM DTT (Invitrogen) and 200 units Superscript II RT. Quantitative ATX expression 
was measured using the TaqMan gene expression probe Hs00196470_m1 in an ABI 7500 
Fast Sequence Detection System (Applied Biosystems). Cycling parameters were: 10 min. at 
95�C followed by 40 cycles of 15 sec. at 95�C and 1 min. at 60�C. The relative product levels 
were quantified using the ddCt method and were normalized to GAPDH expression. Expres-
sion of the ATXα and ATXβ isoforms was measured by RT-PCR using primers (forward 5’- 
ATTACAGCCACCAAGCAAGG-3’ and reverse 5’-TCCCTCAGAGGATTTGTCAT-‘3) located around 
the insertion of the ATXα-specific insert, resulting in a 209 bp fragment for ATXβ and a 366 
bp fragment for ATXα. Human plasmid DNA was used to confirm the specificity of the prim-
ers, which were species-independent.  
Transfection and western blotting
HEK293 cells were transfected with ATX constructs using the calcium phosphate method. 
At 24 hrs after transfection, cells were incubated in serum-free DMEM for 48 hrs. Condi-
tioned medium was centrifuged (5000 rpm for 30 min.) to remove cell debris. Samples were 
analyzed by gel electrophoresis using NuPAGE 4-12% Bis-Tris gels (Invitrogen) under either 
reducing or non-reducing conditions. For Western blot analysis, nitrocellulose filters were 
blocked using 5% non-fat powdered milk and probed with primary antibodies, followed by 
HRP-conjugated secondary antibodies (Dako, Glostrup, Denmark) and proteins were visual-
ized using ECL detection (Amersham, Arlington Heights, IL).
Cell migration
Chemotactic migration of human A2058 melanoma cells was measured in 48-wells Boyden 
chambers (Neuroprobe) as described previously (47). Filters (8 μm pores) were coated with 
gelatin and cells were serum starved overnight, trypsinized and seeded in the upper cham-
ber. ATX (2 ng/ml) was added to the bottom chamber in the presence of 2 μM LPC(18:1) and 
1 mg/ml fatty-acid free BSA. After 4 hrs, cells at the top side were removed and migrated 
cells at the bottom side of the filter were fixed, stained and quantified.
Immunofluorescence
HEK293 cells were transfected with C-terminally Myc-tagged ATXα or ΑΤΧβ. At 24 hrs after 
transfection, cells were fixed with ice-cold ethanol and ATX was visualized by confocal micro-




To measure lysoPLD activity, LPC(18:1) was used as substrate in 50 mM Tris (pH 7.4), 0.01% 
Triton X-100, 25 mM CaCl2, containing 2.5 mM homovanillic acid, 2 units/ml horseradish per-
oxidase, 2 units/ml choline oxidase. After addition of recombinant ATX, the increase in fluo-
rescence was monitored at 37°C (excitation/emission: 355/460 nm), as previously described 
(48). Nucleotide phosphodiesterase activity was measured using pNP-TMP (Sigma-Aldrich) 
as substrate in 50 mM Tris (pH 7.8), 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
1 mg/ml fatty-acid free BSA. After addition of recombinant ATX, the amount of liberated 
para-nitrophenolate (pNP) was determined by the absorbance at 405 nm, as described (37). 
Michaelis-Menten kinetic parameters were determined using GraphPad Prism software.
ELISA
Binding of ATX (α or β) to heparin was evaluated by ELISA in two ways: (a) application of 
ATX to heparin-coated wells of microtiter plates, and (b) competition assays in which ATX 
was first incubated with heparin and then transferred to a heparin-coated plate. A 96-well 
flat-bottom plate was incubated for 16 h with 100 μl of 10 μg/ml heparin in coating buffer. 
As a control, wells were coated for 16 h with 1 μg/ml ATX in 0.05 M carbonate- bicarbonate 
buffer (Sigma-Aldrich, St Louis, MO). After blocking with PBS containing 2% BSA (w/v) for 1 
h, 1 μg/ml ATX (in PBS containing 2% BSA) was added and incubated for 2 hrs. Plates were 
washed six times with PBS and bound ATX was detected using goat anti-ATX IgG  (1:200; 
R&D systems), followed by incubation with alkaline phosphatase-conjugated rabbit anti-
goat IgG (1:2000; Sigma-Aldrich), both for 1 h. Plates were washed six times with PBS, and 
enzyme activity was detected using 100 μl of a p-nitrophenyl phosphate solution (1 mg/ml) 
containing 1 M diethanolamine and 0.5 mM MgCl2 (pH 9.8). Absorbance was measured at 
405 nm. For the competition assay, 0.1 μg/ml ATX was incubated with an increasing con-
tent of heparin (0-1 mg/ml) for 1 h in 100 μl and transferred to a 96-well plate previously 
coated with heparin. Plates were washed six times with PBS before measuring bound ATX, as 
described above.
Surface plasmon resonance
ATX binding to heparin was measured by surface plasmon resonance spectroscopy using 
a Biacore T100 machine (Biacore, GE Healthcare). Recombinant ATXα and ΑΤΧβ were co-
valently coupled to separate flow cells of a CM5 sensor chip at pH 4.0 at roughly equal 
amounts (about 10,000 response units). Increasing concentration of unfractionated heparin 
in running buffer (150 mM NaCl, 20 mM Hepes pH 7.6) were injected across the chip at flow 
rate of 50 μl/min. Injection of 1 M NaCl was used to regenerate the chip surface at the end 
of each cycle. The response units (RUs) for the binding of heparin were evaluated after sub-
traction of the signal in a flow cell of the same sensor chip which has been left uncoated. To 
determine the apparent dissociation constant (Kd), the background-subtracted data were fit 
using a model in which the total binding results from specific binding plus a linear nonspe-







where c is the protein concentration,   
  
Rc the observed response for that specific concentra-
tion,   
  
Bmax the estimated maximal response,   
  
a  the slope of the linear nonspecific compo-
nents and  
  
b the estimated background. The values for non-specific binding and the back-
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ground (  
  
a  and   
  
b ) were kept the same for both ATXα and ΑΤΧβ binding, and only the   
  
Kd  
value was fit individually for each protein. The model used was judged to be 99.9% more 
probable than a model assuming only specific binding, according to the Akaike informa-
tion criterion (AIC). Analysis was performed with GraphPad software, using an average MW 
value for heparin of 15 kDa.
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PREFACE
The proline-rich nature of the polybasic insert of ATXα 
hints at the presence of potential SH3-domain binding 
motifs. SH3-domains are protein modules that mediate 
protein-protein interactions by binding to proline-rich 
sequences (1;2). We hypothesized that the polybasic 
insert could mediate protein-protein interaction(s) of 
ATXα with yet unknown binding partner(s). Here we 
explored the potential of ATX to interact with secreted, 
SH3 domain-containing proteins, which could function to 
modulate ATX localization, activity or binding to integrins 
and heparan sulphate (HS) proteoglycans.
Literature search for secreted proteins - containing an SH3 
domain - revealed melanoma-inhibitory activity (MIA) as 
a single candidate. MIA, or cartilage-derived retinoic acid-
sensitive protein (CD-RAP) is a 12 kDa melanoma-derived 
growth-regulatory protein that is expressed in cartilage as 
well as produced by malignant melanoma cells (3). MIA 
is the first secreted protein containing an SH3 domain 
and represents a serum marker for systemic malignant 
melanoma cells (4-6). MIA has been reported to promote 
melanoma invasion by binding to fibronectin and thereby 
masking the binding site of integrins to these extracellular 
matrix components (7). We therefore set out to examine 
whether ATXα may bind to MIA.
.
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RESULTS
Detailed sequence analysis using SH3 hunter software (8) predicted two potential binding 
motifs (consensus sequence P-x-x-P(-P)) in the polybasic insert of ATXα at residues 331-
334 and 351-354 (Fig. 1A). This suggests that the ATXα insert might indeed function as a 
docking place for SH3-domain based interaction candidates. Moreover, two additional 
motifs are present in the ATXβ sequence; one upstream (residues 204-207) of the polybasic 
insert and one downstream (residues 849-852). However, structural analysis shows that the 
SH3-domain binding motifs of ATXβ are not exposed at the surface of the protein (Fig. 1B). 
This argues against the functionality of these domains, making it unlikely that they mediate 
in protein-protein interactions. 
We tested whether ATXα could interact with MIA by overexpression in HEK293 cells fol-
lowed by immunoprecipitation. As shown in Fig. 2A, ectopically expressed ATXα and MIA 
could be precipitated as a complex. The interaction could only be detected in the cell 
lysate, but not in conditioned medium (data not shown). However, the interaction was not 
specific for ATXα as we detected co-immunoprecipitation between ATXβ and MIA as well. This 
suggests that the interaction is not mediated by the polybasic insert of ATXα. As our struc-
tural analysis excludes an SH3 domain-based interaction mediated by the potential binding 
motifs beyond the polybasic insert, the interaction between MIA and ATX is likely mediated 
via a different, yet unidentified motif. 
Specificity of the ATX-MIA interaction was further tested in MDA-MB-435 cells, which 
endogenously express both ATX (predominantly ATXβ) and MIA (data not shown). Despite 
many efforts, we were unable to detect an interaction between endogenous ATX and MIA 
(Fig. 2B). Next, we tried to verify the interaction in vitro by using recombinant proteins. Again, 
interaction between ATX and MIA could not be detected; neither in a co-immunoprecipita-
tion assay (Fig. 2C) nor by using surface plasmon resonance (data not shown). Furthermore, 
MIA did not affect ATX activity (Fig. 2D). Together, these results argue against MIA as physi-
ological binding partner of ATX in vivo. 
DISCUSSION
The polybasic insert of ATXα contains potential SH3-domain binding motifs, which are 
exposed at the surface of the protein. We hypothesized that the insert could function as a 
docking platform for binding partners and studied the ability of ATX to form a complex with 
MIA, the only secreted SH3-domain containing protein known thus far. Although ATXα and 
MIA were found to interact, ATXβ was found to interact with MIA as well, arguing against the 
involvement of the polybasic insert of ATXα as basis for the interaction. Sequence analysis 
revealed the presence of two potential binding motifs outside the polybasic insert. How-
ever, the ATXβ crystal structure shows that these motifs are not exposed, suggesting that 
the ATX-MIA interaction should be mediated by other, yet unidentified, motifs. 
Although ATX-MIA complexes could be detected when co-expressed, we could not verify 
the ATX-MIA interaction with endogenous or recombinant proteins. This could mean that 
either the interaction occurs only under specific physiological conditions, or might be indi-
rect or very transient and thus hard to detect. However, our results strongly argue against 
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Figure 1: Potential SH3 domain-binding motifs in ATX. (A) Amino acid sequence of ATXα with the 52-residue 
polybasic insert of ATXα underlined. The potential SH3 domain-binding motifs are depicted in bold. Note 
the presence of four motifs (two motifs in the ATXα specific insert, one motif upstream of the insert and 
one motif downstream of the insert) and the presence of an R-R-R-K motif in the polybasic insert at resi-
dues 358-361 (a consensus site of R-x-x-K has been described as a novel mode of ligand recognition by SH3 
domains (15)). ATXα transcript ID: ENSP00000259486. (B) Space-filling model of the ATXβ crystal structure, 
showing the N-terminal SH3 domain-binding motif (PVYPTK) in pink and the C-terminal motif (FILPHRP) in 
purple. Both motifs are not exposed to the surface, making it very unlikely that they will serve as interac-
tion motifs. See ref. (13) for more details about the ATXβ crystal structure.
A
  1 MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCK  60 
 61 GRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHC 120 
121 SEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMK 180 
181 KGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDA 240 
241 TFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHER 300 
301 PSVYAFYSEQPDFSGHKYGPFGPEESSYGSPFTPAKRPKRKVAPKRRQERPVAPPKKRRR 360 
361 KIHRMDHYAAETRQDKMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCD 420 
421 RTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQH 480 
481 LPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVF 540 
541 VGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEV 600 
601 TRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRT 660 
661 RYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCL 720 
721 AYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASER 780 
781 NGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGP 840 
841 LSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPE 900 
901 ILTLKTYLHTYESEI                                              915 
N-terminal SH3 mof C-terminal SH3 mof
B
a functional ATX-MIA interaction. Nevertheless, it is still possible that the binding motifs in 
the polybasic insert play a role in the interaction of ATX with other (secreted) proteins. MIA 
is a member of a recently identified protein family of extracellular SH3 domain containing 
proteins. The MIA homologous proteins TANGO, MIA-2 and OTOR, whose biological func-
tions remain to be determined, are part of this family as well (9). It is possible that one of 
these family members or another binding partner is able to interact with ATXα, a hypothesis 
that is worth exploring. It is noteworthy that the furin cleavage site is located in the middle 
of both motifs, pointing to a possible role of furin cleavage in modulating the interaction of 
ATXα and putative binding partners. 
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Figure 2: Analysis of the interaction between ATX and MIA. (A) Ectopic expression of MIA and ATXα or ATXβ 
in HEK293 cells. Pull down of ATXα or ATXβ from cell lysates results in co-immunoprecipitation of MIA. 
(B) Endogenous expression of ATX and MIA in MDA-MB-435 cells.  Pull down of MIA or ATX does not result 
in co-immunoprecipitation of respectively ATX or MIA. Upper and middle panel: anti-MIA pull down and 
input blot (negative control: goat IgG, beads only, goat serum). Lower panel: anti-ATX pull down (negative 
control: beads only). M: conditioned medium; L: lysate; + : antibody IP; - : negative control (IP without 
antibody). Note that MDA-MB-435 cells express MIA and ATX, predominantly ATXβ (data not shown). 
(C) Pull down of recombinant ATX or MIA does not result in the detection of a protein complex. Note the 
presence of MIA in the residual supernatant after ATX immunoprecipitation. (D) PDE activity, as measured 
by the hydrolysis of 1 mM bis-pNPP. The activity of ATXα and ATXβ is not affected by MIA. Pre-incubation 
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Anti-MIA polyclonal antibody was obtained from R&D Systems; anti-ATX C-term poly-
clonal antibody was homemade, raised against the C-terminus of zebrafish ATX epitope 
CEDESKWVEELMKTHTAR; anti-ATX monoclonal antibodies 3D1 (10) and 5E5 (11) were a 
generous gift from Dr. J. Aoki. HRP-conjugated secondary antibodies were obtained from 
Dako, the ECL detection kit from Amersham and bis(p-nitrophenyl)phosphate (bis-pNPP) 
was obtained from Sigma.
Cells
HEK293 and MDA-MB-435 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal calf serum. For overexpression studies, HEK293 cells were transfected 
using the calcium phosphate transfection method. 
Constructs
Human ATXβ was ligated in the pcDNA3 vector containing a 3’ Myc tag, as previously 
described (12). Human ATXα, ligated in the pcDNA3 vector containing a 3’ Myc-His tag, was 
a generous gift from Dr. Andree Blaukat (Merck-Serono, Darmstadt, Germany). MIA, ligated 
in the pCMX-PL1 vector, was a generous gift from Dr. Anja-Katrin Bosserhoff. 
Recombinant proteins
Human ATXα and ATXβ were cloned in pcDNA5-FRT (Invitrogen) with a C-terminal Myc-tag 
and a 6xHis-tag. HEK293 cells stably expressing ATXα or ATXβ were generated using the 
FLPin system (Invitrogen). Recombinant His-tagged ATX was purified from conditioned 
HEK293 medium as previously described (13). Recombinant MIA was a generous gift from 
Dr. Anja-Katrin Bosserhoff.
Co-immunoprecipitation assay and Western Blotting
At 48 hrs after transfection, RIPA cell lysates and conditioned medium samples were col-
lected and centrifuged (13,000 rpm for 30 min. at 4°C). For ATX IP, samples were incubated 
with the anti-ATX monoclonal antibody 5E5 coupled to sepharose 4B beads as described 
previously (14), and tumbled at 4°C for 5 hours. For MIA IP, samples were incubated with 
the anti-MIA polyclonal antibody and tumbled at 4°C for 4 hours. Subsequently, they 
were analyzed by gel electrophoresis using NuPAGE 4-12% Bis-Tris gels (Invitrogen) under 
reducing conditions. Proteins were transferred to nitrocellulose membranes, blocked using 
5% non-fat powdered milk and probed with primary antibodies; anti-MIA polyclonal anti-
body, anti-ATX C-term polyclonal antibody, anti-ATX monoclonal antibody 3D1. Subsequent-
ly, the membranes were probed with HRP-conjugated secondary antibodies and proteins 
were visualized using ECL detection.
For immunoprecipitation studies using recombinant protein, 13.9 ug ATX was first incubated 
with anti-ATX antibody 5E5 coupled to beads and tumbled for 1 hour at 4°C. Subsequently, 
an equimolar amount of recombinant MIA was added for another 2 hours, tumbling at 4°C. 
Proteins were analyzed by gel electrophoresis as discussed above.
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Phosphodiesterase activity assay
Phosphodiesterase activity was measured using 1 mM bis-pNPP in Tris-buffered saline (140 
mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 50 mM Tris pH 8.0) containing 1 mg/ml 
fatty-acid free BSA. The amount of liberated para-nitrophenolate (pNP) was determined by 
reading the absorbance at 405 nm, as previously described (12). 
ACKNOWLEDGEMENTS
We thank Anja-Katrin Bosserhoff (University of Regensburg, Germany) for providing MIA 
constructs and recombinant protein, Alex Fish (Netherlands Cancer Institute, Amsterdam) 
for performing surface plasmon resonance experiments, Winny Grernrum (Netherlands 
Cancer Institute, Amsterdam) for excellent technical assistance and Dr. J. Aoki  (Tohoku Uni-





 1.  Mayer, B. J. (2001) J. Cell Sci. 114, 1253-1263
 2.  Ren, R., Mayer, B. J., Cicchetti, P., and Baltimore, 
D. (1993) Science 259, 1157-1161
 3.  Blesch, A., Bosserhoff, A. K., Apfel, R., Behl, C., 
Hessdoerfer, B., Schmitt, A., Jachimczak, P., Lott-
speich, F., Buettner, R., and Bogdahn, U. (1994) 
Cancer Res 54, 5695-5701
 4.  Bosserhoff, A. K., Kaufmann, M., Kaluza, B., 
Bartke, I., Zirngibl, H., Hein, R., Stolz, W., and 
Buettner, R. (1997) Cancer Res 57, 3149-3153
 5.  Dietz, U. H. and Sandell, L. J. (1996) J Biol Chem 
271, 3311-3316
 6.  Lougheed, J. C., Holton, J. M., Alber, T., Bazan, J. 
F., and Handel, T. M. (2001) Proc Natl Acad Sci U 
S A 98, 5515-5520
 7.  Stoll, R., Renner, C., Zweckstetter, M., Bruggert, 
M., Ambrosius, D., Palme, S., Engh, R. A., Golob, 
M., Breibach, I., Buettner, R., Voelter, W., Holak, 
T. A., and Bosserhoff, A. K. (2001) EMBO J 20, 
340-349
 8.  Ferguson, C. G., Bigman, C. S., Richardson, R. 
D., van Meeteren, L. A., Moolenaar, W. H., and 
Prestwich, G. D. (2006) Org Lett 8, 2023-2026
 9.  Stoll, R. and Bosserhoff, A. (2008) Curr Protein 
Pept Sci 9, 221-226
 10.  Tanaka, M., Kishi, Y., Takanezawa, Y., Kakehi, Y., 
Aoki, J., and Arai, H. (2004) FEBS Lett 571, 197-
204
 11.  Nakasaki, T., Tanaka, T., Okudaira, S., Hirosawa, 
M., Umemoto, E., Otani, K., Jin, S., Bai, Z., Haya-
saka, H., Fukui, Y., Aozasa, K., Fujita, N., Tsuruo, 
T., Ozono, K., Aoki, J., and Miyasaka, M. (2008) 
Am J Pathol 173, 1566-1576
 12.  van Meeteren, L. A., Ruurs, P., Christodoulou, E., 
Goding, J. W., Takakusa, H., Kikuchi, K., Perrakis, 
A., Nagano, T., and Moolenaar, W. H. (2005) J 
Biol Chem 280, 21155-21161
 13.  Hausmann, J., Kamtekar, S., Christodoulou, E., 
Day, J. E., Wu, T., Fulkerson, Z., Albers, H. M., van 
Meeteren, L. A., Houben, A. J., van Zeijl, L., Jan-
sen, S., Andries, M., Hall, T., Pegg, L. E., Benson, 
T. E., Kasiem, M., Harlos, K., Kooi, C. W., Smyth, 
S. S., Ovaa, H., Bollen, M., Morris, A. J., Mool-
enaar, W. H., and Perrakis, A. (2011) Nat Struct 
Mol Biol 18, 198-204
 14.  Cavalli, S., Houben, A. J., Albers, H. M., van Til-
burg, E. W., de Ru, A., Aoki, J., van Veelen, P., 
Moolenaar, W. H., and Ovaa, H. (2010) Chembio-
chem 11, 2311-2317
 15.  Liu, Q., Berry, D., Nash, P., Pawson, T., McGlade, 






Anna J.S. Houben1 
1Division of Cell Biology, 
The Netherlands Cancer Institute, 
Amsterdam, The Netherlands
PREFACE
Autotaxin (ATX) is an extracellular multidomain protein 
that functions as a lysophospholipase D to produce lyso-
phosphatidic acid (LPA) by hydrolyzing lysophosphati-
dylcholine (LPC). LPA is a small bioactive lipid that acts 
on specific receptors in the cell membrane and thereby 
elicits a great variety of cellular responses (1). LPA recep-
tor signaling activates proliferation, migration and survival 
pathways and has been implicated in various physiologi-
cal and pathological processes (2;3). ATX is the major LPA- 
producing enzyme and is essential for normal develop-
ment (4;5). The studies described in this thesis aim at 
characterizing the biochemical and functional proper-
ties of ATX in order to advance our understanding of the 
molecular actions of ATX in (patho)physiology. Here, the 
findings of these studies are summarized and their impli-
cations for further research are discussed. 
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The ATX-LPA receptor axis in cancer
Since the discovery of ATX as an autocrine motility factor for melanoma cells (6), many sub-
sequent studies have focused on ATX and LPA receptor signaling in cancer. In chapter 2, the 
evidence for a role of the ATX-LPA receptor axis in cancer is summarized. In short, elevated 
or aberrant expression of ATX is found in several human cancers (7-15), overexpression of 
ATX or LPA receptors in mouse tumor models stimulates tumor growth and invasion (16-
23), while knockdown has the reverse effect (17;18;24;25). Moreover, ATX overexpression 
studies have shown an effect of ATX on tumor vascularization (21), consistent with a role for 
ATX-LPA receptor signaling in vascular development (4;5;26;27). Recently, ATX was shown to 
drive vascular development in zebrafish through LPA1 and LPA4 (28). 
Emerging evidence indicates that LPA signaling needs to collaborate with other proto- 
oncogenic events to induce cell transformation (19;20;22;24;25). For example, trans- 
genic overexpression of ATX and LPA receptors allows accumulation of secondary mutations, 
thereby increasing the probability of acquiring (pro-)oncogenic mutations and subsequent 
tumor development (19). On top of this, ATX can contribute to tumor growth and angio-
genesis (16-23). This suggests that ATX-LPA receptor signaling plays an oncogenic role by 
affecting multiple hallmarks of cancer (29) and raises the question of whether aberrant ATX 
and/or LPA receptor expression is associated with clinical outcome in cancer. 
ATX expression profiling in breast cancer
ATX-LPA receptor signaling in breast cancer has gained special interest since overexpression 
of ATX or individual EDG-family LPA receptors in mouse mammary glands promotes invasive 
and metastatic mammary cancer (19). Little is known, however, about ATX in human breast 
cancer. We have explored the prognostic value of ATX protein expression in human breast 
cancer in chapter 3. We find that virtually all tumors are ATX positive, although there is 
no significant correlation with clinico-pathological characteristics or patient outcome. Thus, 
ATX expression does not serve as a prognostic factor in breast cancer, despite the fact that 
studies in mice suggest a causal link between ATX-LPA receptor signaling and mammary 
cancer initiation (19) and progression (16;17). 
Somewhat unexpectedly, analysis of a publicly available dataset of over 2400 human breast 
tumor samples (www.kmplot.com (30)) shows better survival for patients with high ATX 
expression, which differs from our findings. As discussed above, several studies suggest that 
LPA signaling needs to collaborate with other proto-oncogenic events (19;20;22;24;25), thus 
the intrinsic molecular features of the tumor cell and its microenvironment might influ-
ence the outcome of LPA signaling. Consequently, in this complex signaling network some 
of the cellular responses of ATX-LPA signaling may positively influence tumorigenesis (e.g. 
cell proliferation, migration and survival pathways), while others could have a negative ef-
fect (e.g. stimulation of immune responses). Recent evidence shows that, depending on 
the LPA receptor profile, LPA can exert inhibitory effects (31). In addition, breast cancer is a 
heterogeneous disease with different histological and molecular subtypes influencing clini-
cal prognosis (32). Thus, the seemingly contradictory results may reflect the dual effects of 
ATX-LPA receptor signaling on tumorigenesis as well as the heterogeneity of breast tumors. 
It is important to note that high ATX expression does not necessarily imply elevated LPA 
levels and enhanced receptor signaling. Upregulation of LPA2 expression has been detected 
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in human invasive ductal breast carcinoma (33), pointing to the importance of LPA receptor 
expression profiles in determining the outcome of ATX-LPA signaling in breast cancer. To 
address this issue in future studies, a more comprehensive approach is required. Such an 
analysis should preferably focus on both LPA receptor and ATX expression profiles and, in 
addition, measure ATX activity levels in the tumor-stroma microenvironment. 
ATX activity profiling 
Aside from cancer, LPA receptor signaling has been implicated in various other pathologi-
cal processes. These include obesity (34;35), cardiovascular disease (36;37), neuropathic 
pain (38), fibrosis (39;40), hydrocephalus (41) and cholestatic pruritus (42). Thus, measuring 
local ATX activity levels could have diagnostic potential in various diseases. Therefore, we 
developed a fluorescent ATX activity-based probe (ATX-ABP) to detect and quantify ATX 
activity in biological fluids. In chapter 4 we describe the development and characteriza-
tion of our first generation probe, designed to covalently react with the ATX active site 
upon recognition and activation. This allows the study of ATX based on catalytic activity 
instead of expression levels. We show that ATX-ABP labeling is specific as well as activity-, 
concentration- and time-dependent. Moreover, the probe can be used for inhibitor profiling 
and screening of ATX activity in human plasma, indicating the potential of ATX-ABP to be 
developed into a diagnostic reagent. 
A drawback of our probe is the low in vivo labeling efficiency, which is circumvented by 
combining ATX-ABP labeling with an affinity-purification step. However, this method is time 
consuming and cannot be automated for high-throughput ATX activity screening of a large 
number of samples. As a result, there is a need for optimization to enable direct and effi-
cient labeling of ATX in complex biological fluids. As the first ATX activity probe developed so 
far, ATX-ABP has the potential to evolve into second-generation probes. Making use of the 
recent insights into the ATX crystal structure (43;44), the challenge now is to develop activ-
ity reporters with increased sensitivity and efficiency. These efforts should lead the way to 
reagents that will be useful to proof the diagnostic potential and clinical application of ATX.
A second outstanding question is whether ATX acts in an autocrine or paracrine manner, 
or both. For instance in the tumor microenvironment: do tumor cells produce ATX to acti-
vate their own LPA receptors and/or LPA responsive stromal cells? Or is ATX predominantly 
produced by stromal cells to activate tumor cells? Most likely, there is extensive interplay 
between tumor cells and the microenvironment, combining both autocrine and paracrine 
signaling. To increase complexity even more, LPA signaling can stimulate fibroblasts to 
produce many mediators of tissue remodeling and inflammation. These include growth fac-
tors, chemokines, cytokines, proangiogenic factors and metalloproteases, that exert both 
autocrine and paracrine functions (45). In addition, ATX is implicated in immune responses 
by promoting lymphocyte-endothelial interactions and lymphocyte homing into secondary 
lymphoid organs (46;47). This shows that the effect of ATX-LPA receptor signaling is the 
result of a complex network of signaling events and the development of second-generation 
ATX activity probes is awaited to reveal the secrets of this largely unexplored field. 
ATX isoforms and localized LPA signaling
Alternative splicing of the ENPP2 gene results in distinct ATX isoforms (48-50). Whether 
these isoforms might display functional differences has long remained elusive. In chapter 
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5 we studied the biochemical properties of the ATXα isoform, which is of special interest 
since it harbors a 52-residue polybasic insert of unknown function in the heart of the PDE 
domain. We find that the ATXα insert contains a consensus cleavage site for the endo- 
protease furin as well as putative heparin-binding motifs and we show that secreted ATXα 
undergoes proteolytic cleavage by furin or a furin-like protease. Previously, cleavage of ATXα 
was suggested to induce rapid degradation (48). In contrast, our data show that cleaved 
ATXα remains structurally and functionally intact due to a strong and extended interaction 
surface between both cleavage fragments. ATXα cleavage seems to occur extracellulary, 
which suggests cleavage by a cell-surface or soluble protease. The furin-like protease PACE4 
is of special interest, as it is known to bind heparin and to associate with the extracellular 
matrix (51). It is tempting to hypothesize that PACE4 is responsible for proteolytic proces-
sing of ATXα, which might serve to regulate the ATXα-heparin interaction. The low expres-
sion levels seem to contradict a functional role for ATXα. However, we show that ATXα is 
expressed at considerably high levels in several tumor cell lines. This might point to an 
isoform-specific role for ATXα in tumors, an interesting area for further research.  
ATXα has a roughly ten-fold higher affinity for heparin than ATXβ, owing to the polybasic 
nature of the ATXα specific insert. Since heparin is structurally very similar to heparan 
sulphate (HS), ATX is expected to bind to cell membrane-bound HS proteoglycans. This 
suggests an isoform-specific recruitment of ATX to target cells, which subsequently could 
induce a local production and delivery of LPA to its receptors. Interaction of ATX with 
target cells, either via integrins or direct binding to the plasma membrane, is a mechanism 
that has recently attracted much interest (43;44;46;52). Our heparin-binding data suggest a 
third mechanism of ATX binding to target cells. Interestingly, heparin enhanced ATXα activity 
about two-fold, without affecting ATXβ. This may point to a catalytic regulatory mechanism 
and, in combination with an isoform-specific mechanism of localized LPA production and 




ATX-LPA receptor signaling plays a widespread role in physiological and pathological pro-
cesses and therefore is of therapeutic interest. A comprehensive biochemical analysis of its 
mode of action is crucial to develop future therapeutic and clinical applications. Of special 
interest is the oncogenic potential of the ATX-LPA receptor axis (described in chapter 2), 
which has mainly emerged from studies in mice. The results from our ATX protein expres-
sion analysis in human breast cancer (chapter 3) indicate that we should primarily focus on 
LPA receptor levels, combined with ATX expression or activity profiling, to unravel the prog-
nostic value of ATX-LPA receptor signaling in cancer. For the latter purpose, we developed an 
ATX activity-based probe (chapter 4), which holds promise for use in a clinical setting. The 
results described in chapter 5 show increased affinity of ATXα for binding to heparin, sug-
gesting isoform-specific localized LPA production and signaling via interaction of ATXα with 
target cells by binding to HS proteoglycans.
Both ATX, as an extracellular phosphodiesterase, and LPA receptors, belonging to the 
highly druggable GPCR superfamily, are attractive targets for therapeutic intervention. Small- 
molecule ATX inhibitors with in vivo efficacy have already been described (44;53;54) 
and major insights into the catalytic function of ATX have been provided by the recently 
determined ATX crystal structure (43;44). Studies focusing on both fundamental and clini-
cal aspects should boost our understanding of the ATX-LPA receptor signaling axis. This will 
enable us to study the widespread diagnostic potential of ATX activity and/or LPA receptor 
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NEDERLANDSE SAMENVATTING VOOR LEKEN 
Een organisme bestaat uit vele cellen die voortdurend met elkaar communiceren en 
samenwerken. Hiervoor gebruiken cellen verschillende signaleringsmoleculen. Een voor-
beeld hiervan is LPA (lysofosfatide-zuur), een vetachtig stofje dat wordt geproduceerd door 
het enzym autotaxine (ATX). LPA is belangrijk voor de communicatie tussen de cel en zijn 
omgeving. Door de binding van LPA aan LPA receptoren op de celmembraan worden pro-
cessen in de cel geactiveerd, zoals proliferatie (het vermenigvuldigen van cellen), migratie 
(beweging van cellen) en overleving. 
ATX wordt door cellen in het lichaam uitgescheiden in het extracellulaire milieu (lichaams-
vloeistoffen, zoals bloed en hersenvocht). ATX is van kritisch belang gedurende de embryo-
nale ontwikkeling en daarnaast speelt ATX een belangrijke rol in diverse ziektes zoals kanker, 
ontstekingen en overgewicht. Het is echter niet bekend wat de precieze functie is van ATX 
in zowel gezond als ziek weefsel. Het onderzoek beschreven in dit proefschrift heeft als doel 
het bestuderen van ATX op moleculair niveau, door middel van biochemische en functionele 
studies. Deze resultaten zullen bijdragen aan het vergroten van de algemene kennis over 
de werking van ATX en daarmee inzicht geven hoe ATX bijdraagt aan verschillende ziekte-
processen.
Hoofdstuk 1 van dit proefschrift geeft een algemene inleiding over ATX en LPA, met speciale 
aandacht voor de biologische functie, de enzymatische activiteit en biochemische aspec-
ten van ATX en LPA, en de rol hiervan in gezonde en zieke weefsels. In hoofdstuk 2 wordt 
een literatuuroverzicht gegeven over de specifieke rol van ATX en LPA in kanker. Studies in 
gekweekte cellen en muizen suggereren dat ATX en LPA de groei en progressie van tumoren 
positief beïnvloeden. Vervolgens wordt in hoofdstuk 3 onderzocht of ATX een voorspellende 
factor is in de progressie van borstkanker in de mens. Omdat eerder onderzoek heeft laten 
zien dat excessieve ATX-LPA signalering in de muis de groei van tumoren en ontwikkeling 
van uitzaaiingen stimuleert, werd verwacht dat het meten van ATX niveaus in menselijke 
tumoren als een maat voor tumor agressiviteit zou kunnen functioneren. De resultaten van 
dit onderzoek laten zien dat het overgrote deel van de tumoren inderdaad verhoogde ATX 
niveaus heeft, maar dit correleert niet met de klinische en prognostische karakteristieken 
van de patiënt. Er moet dus geconcludeerd worden dat ATX niveaus niet gebruikt kunnen 
worden als voorspellende factor voor overlevingskansen van borstkanker-patiënten. 
LPA receptor signalering wordt naast kanker in verband gebracht met meerdere ziektes, 
zoals bijvoorbeeld hart- en vaatziekten. Het meten van de ATX activiteit als maat voor LPA 
productie kan dus van groot belang zijn in verschillende ziektes. In hoofdstuk 4 wordt de 
ontwikkeling en karakterisatie van een ‘activiteitsprobe’ als sensor voor ATX beschreven. 
De probe reageert met het enzymatische domein en dit heeft als voordeel dat in plaats 
van alleen de aanwezigheid, juist specifiek de activiteit van ATX gemeten kan worden. Onze 
studie laat zien dat deze eerste generatie probe gebruikt kan worden om ATX activiteit te 
meten in menselijk bloedplasma. De uitdaging voor de toekomst is om deze probe verder 




In hoofdstuk 5 wordt onderzoek verricht naar de specifieke aspecten van ATXα, een speciale 
variant (isovorm) van het ATX eiwit die oorspronkelijk is ontdekt in huidkanker cellen. Het 
interessante aan ATXα is de aanwezigheid van een unieke insertie van 52 aminozuren in 
het hart van het enzymatische domein. Onze resultaten tonen aan dat ATXα precies in deze 
insertie wordt geknipt door het enzym furine. Hierdoor zou men verwachten dat het ATXα 
eiwit uit elkaar valt en daardoor de enzymatische activiteit geremd wordt. Dit is echter niet 
het geval, wat verklaard kan worden door de zeer sterke intramoleculaire interacties in het 
enzymatische domein van ATXα. Ten tweede blijkt het ATXα eiwit een zeer sterke affiniteit 
te hebben voor heparine, een stofje dat sterke overeenkomsten vertoont met een bepaalde 
groep moleculen (de heparaansulfaat proteoglycanen) op de celmembraan. Dit suggereert 
dat de ATXα variant, in contrast met het ‘normale’ ATX, sterk aan de celmembraan kan 
binden. Bovendien stimuleert deze heparine binding de functie van ATXα, namelijk het 
produceren van LPA. Dit wijst op een isovorm-specifieke functie: het reguleren van de LPA 
productie op de celmembraan vlakbij de LPA receptoren.
In hoofdstuk 6 wordt bestudeerd of de unieke insertie van de ATXα variant kan functio-
neren als bindingsplaats voor andere eiwitten. Zo’n interactie zou de functie en/of lokalisa-
tie van ATXα kunnen beïnvloeden. Het aminozuur proline, dat in grote getale aanwezig is in 
de insertie van ATXα, kan functioneren als herkenningsplaats voor de binding van specifieke 
eiwitten die een zogenaamd SH3 domein bevatten. In het extracellulaire milieu, de plek 
waar ATX zijn functie uitoefent, is er maar een eiwit bekend met een SH3 domein, namelijk 
het eiwit ‘MIA’. Hoewel we zien dat ATXα en MIA aan elkaar kunnen binden onder artificiële 
omstandigheden, hebben we dit niet kunnen aantonen in de ‘normale’ cellulaire omgeving. 
Dit suggereert dat ATXα en MIA waarschijnlijk niet als bindingspartners functioneren, maar 
het sluit echter niet uit dat ATXα aan andere eiwitten kan binden. 
De resultaten beschreven in dit proefschrift vergroten ons inzicht in het werkingsmecha-
nisme van ATX. Dergelijke studies zullen een belangrijke bijdrage leveren aan het ont- 
rafelen van de functie van ATX-LPA receptor signalering in zowel gezonde als zieke weefsels. 
Uiteindelijk zal deze kennis vertaald moeten worden naar de ontwikkeling van diagnostische 
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Het enzym autotaxine (ATX) komt tot expressie in borstkankerweefsel, maar het 
expressieniveau van ATX is geen voorspeller van klinische uitkomst (dit proefschrift)
 
Activiteits-afhankelijke probes bieden een praktische methode om de activiteit van  ATX 
in biologische vloeistoffen te meten (dit proefschrift)  
De lange isovorm van ATX (ATXα) heeft een unieke insertie in het katalytisch domein.
Klieving van deze insertie door furine resulteert niet in verlies van activiteit, maar zou 
kunnen dienen om de interactie tussen ATXα en heparaansulfaat proteoglycanen te 
reguleren (dit proefschrift)
De interactie tussen ATXα en heparine suggereert een nieuw mechanisme voor 
gelocaliseerde LPA productie en signalering door binding van ATXα aan heparaansulfaat 
proteoglycanen op de celmembraan (dit proefschrift)
Een deletie van 18 aminozuren in het katalytisch domein van ATX ten opzichte van zijn 
nucleotide pyrofosfatase/fosfodiestedase (NPP) familieleden veroorzaakt de vorming 
van een bindingsgroeve voor lysofosfolipiden. De aanwezigheid van deze aminozuren in 
de NPP1 en NPP3 familieleden van ATX  verklaart waarom zij niet kunnen functioneren 
als een lysofosfolipase enzym (Hausmann et al, Nat Struct Mol Biol 2011; 18(2): 198-204 
en Nishimasu et al, Nat Struct Mol Biol 2011; 18(2): 205-12)
De sterke interactie tussen het inactieve nuclease domein en het actieve katalyt-
ische domein van ATX is een slimme evolutionaire oplossing om de stabiliteit van het 
katalytische domein te waarborgen (Moolenaar & Perrakis, Nat Rev Mol Cell Biol 2011; 
12(10): 674-79)
Studies naar het gedrag van tumoren zou niet alleen de eigenschappen van de 
tumorcellen zelf moeten omvatten, maar moet tevens de bijdrage van de tumor omgev-
ing behelzen (Hanahan & Weinberg, Cell 2011; 144(5): 646-74)
Afwezigheid van bewijs is niet hetzelfde als bewijs van afwezigheid (Altman & Bland, 
B M J 1995; 311(7003): 485) 
In tegenstelling tot de verwachting dat wetenschap eenduidige antwoorden oplevert, 
zijn er meestal vele antwoorden en nog meer vragen waar men genoegen mee moet 
nemen
Het humane genoom kan worden gezien als een boek van 23 hoofdstukken (de 
“chromosomen”) met in totaal meer dan drie biljoen letters (de “nucleotiden”). Het  feit 
dat we pas zo’n 2% van deze tekst begrijpen, geeft aan dat we nog lang niet klaar zijn 
met lezen
Als je niet leert van je fouten, doe je iets fout (Johan Cruijff)
De wereld is een boek en degenen die niet reizen, lezen maar één pagina (Aurelius 
Augustinus, Romeins filosoof, 354-430)
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The enzyme autotaxin (ATX) is expressed in breast cancer, but ATX expression levels are 
not a prognostic factor for clinical outcome (this thesis)
Activity-dependent probes are useful tools to monitor ATX activity in biological fluids 
(this thesis)  
The long isoform of ATX (ATXα) contains a unique insertion in the catalytic domain. 
Cleavage of this insert by furin does not result in loss of activity, but could serve to 
regulate the interaction between ATXα and heparan sulfate proteoglycans (this thesis)
Binding of ATXα to heparin suggests a new mechanism for localized LPA production and 
signaling by binding of ATXα to heparan sulfate proteoglycans at the cell membrane 
(this thesis)
Deletion of an 18-amino acid stretch in the catalytic domain of ATX compared to its 
nucleotide pyrophosphatase/phosphodiesterase (NPP) family members allows the 
formation of a lysophospholipid binding pocket. The presence of this stretch explains 
why the NPP1 and NPP3 family members of ATX cannot function as a lysophospholipase 
(Hausmann et al, Nat Struct Mol Biol 2011; 18(2): 198-204 and Nishimasu et al, Nat 
Struct Mol Biol 2011; 18(2): 205-12)
The rigid interaction between the inactive nuclease domain and the active catalytic 
domain in the ATX structure is a clever evolutionary solution to maintain stability of the 
catalytic domain (Moolenaar & Perrakis, Nat Rev Mol Cell Biol 2011; 12(10): 674-79)
Studies to understand the behavior of tumor cells should not solely focus on the traits 
of tumor cells, but instead must include the contributions of the tumor environment as 
well  (Hanahan & Weinberg, Cell 2011; 144(5): 646-74)
Absence of evidence is not evidence of absence (Altman & Bland, B M J 1995; 311(7003): 
485) 
Contrary to the expectation that science will reveal one single clear answer, more often 
than not scientists have to be satisfied with several answers and even more questions 
as a result
The human genome is like a book of 23 chapters (the “chromosomes”) with in total over 
three billion letters (the “nucleotides”). The fact that we comprehend only around 2% 
of this text indicates that we have not finished reading yet
If you do not learn from your mistakes, you make a mistake (Johan Cruijff)
The world is a book, and those who do not travel read only one page (Aurelius 
Augustine, Roman philosopher, 354-430))
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